---
document_datetime: 2025-06-26 14:40:03
document_pages: 68
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/veklury-h-c-005622-ii-0053-g-epar-assessment-report-variation_en.pdf
document_name: veklury-h-c-005622-ii-0053-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 72.2340542
conversion_datetime: 2025-12-23 01:35:39.756378
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2025 EMA/150907/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Invented name: Veklury

International non-proprietary name: remdesivir

Procedure No. EMEA/H/C/005622/II/0053/G

Marketing authorisation holder (MAH): Gilead Sciences Ireland UC

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6      |                                                                                                           |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................7                         |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8             |
| 2.1.2. About the product............................................................................................10      |                                                                                                           |
| 2.1.3. The development programme                                                                                            | ...........................................................................10                             |
| 2.1.4. General comments on compliance with GCP........................................................10                    |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................10            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                               |
| 2.2.2. Conclusion on the non-clinical aspects................................................................10             |                                                                                                           |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11      |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................24         |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................24      |
| 2.4.1. Main study: GS-US-540-5823 (CARAVAN)                                                                                 | ..........................................................24                                              |
| 2.4.2. Discussion on clinical efficacy............................................................................44        |                                                                                                           |
| 2.4.3. Conclusions on the clinical efficacy.....................................................................47          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................47    |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................52                          |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................53                            |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................53   |
| 2.6. Risk management plan........................................................................................53         |                                                                                                           |
| I.1. Additional Pharmacovigilance Activities................................................................58              |                                                                                                           |
| 2.7. Update of the Product information                                                                                      | ........................................................................59                                |
| 2.7.1. User consultation.............................................................................................60     |                                                                                                           |
| 2.7.2. Additional monitoring.......................................................................................60       |                                                                                                           |
| 3. Benefit-Risk Balance..............................................................................60                     |                                                                                                           |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................60             |
| 3.1.1. Disease or condition.........................................................................................60      |                                                                                                           |
| 3.1.2. Available therapies and unmet medical                                                                                | need.......................................................60                                             |
| 3.1.3. Main clinical study                                                                                                  | ...........................................................................................61             |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................61          |
| 3.3. Uncertainties and limitations about favourable effects.............................................63                  |                                                                                                           |
| 3.4. Unfavourable effects...........................................................................................64      |                                                                                                           |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................64                                                               |
| 3.6. Effects Table......................................................................................................65  |                                                                                                           |
| 3.7. Benefit-risk assessment and discussion.................................................................65              |                                                                                                           |
| 3.7.1. Importance of favourable and unfavourable                                                                            | effects..............................................65                                                   |
| 3.7.2. Balance of benefits and risks.............................................................................66         |                                                                                                           |
| 3.8. Conclusions                                                                                                            | .......................................................................................................67 |

<div style=\"page-break-after: always\"></div>

4. Recommendations .................................................................................  67

<div style=\"page-break-after: always\"></div>

## List of abbreviations

%CV

percentage coefficient of variation

AE

adverse event

AIDS

acquired immunodeficiency syndrome

ALT

alanine aminotransferase

aPTT

activated partial thromboplastin time

AST

aspartate aminotransferase

AUCtau

area under the concentration versus time curve over the dosing interval

CDC

Centres for Disease Control and Prevention

CI

confidence interval

CoV

coronavirus

COVID-19

coronavirus disease 2019

ECMO

extracorporeal membrane oxygenation

eGFR

estimated glomerular filtration rate

GMR

geometric mean ratio

ET

endotracheal tube

ICU

intensive care unit

i.e.

id est = that is

INR

international normalized ratio

IV

intravenous

m

Module

max

maximum

MERS

Middle East respiratory syndrome

NP

nasopharyngeal

OP

oropharyngeal

PCR

polymerase chain reaction

PD

pharmacodynamics

PK

pharmacokinetic(s)

PEWS

Paediatric Early Warning Score

PK

pharmacokinetic(s)

PopPK

population pharmacokinetic

Q1

first quartile

Q3

third quartile

<div style=\"page-break-after: always\"></div>

RDV remdesivir (GS-5734™) RNA ribonucleic acid SBECD sulfobutylether β -cyclodextrin sodium SAE serious adverse event SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 SD standard deviation SmPC summary of product characteristics US United States Vc central volume of distribution Vp peripheral volume of distribution

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Gilead Sciences Ireland UC submitted to the European Medicines Agency an application for a group of variations on 28 November 2023.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Grouped application comprising two extensions of indication to include treatment of paediatric patients weighing at least 1.5 kg for VEKLURY, based on final results from study GS-US-540-5823; this is a Phase 2/3 single-arm, open-label study to evaluate the  safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to &lt; 18 years of age with COVID-19;  As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted.

The group of variations requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision P/0439/2023 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0439/2023 was completed. The PDCO issued an opinion on compliance for the PIP.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP was:

Rapporteur:

Janet Koenig

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 28 November 2023 |
| Start of procedure                                   | 23 December 2023 |
| CHMP Rapporteur Assessment Report                    | 20 February 2024 |
| PRAC Rapporteur Assessment Report                    | 23 February 2024 |
| PRAC members comments                                | 28 February 2024 |
| Updated PRAC Rapporteur Assessment Report            | 29 February 2024 |
| PRAC Outcome                                         | 7 March 2024     |
| CHMP members comments                                | 11 March 2024    |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 15 March 2024    |
| Request for supplementary information (RSI)          | 21 March 2024    |
| CHMP Rapporteur Assessment Report                    | 21 November 2024 |
| Updated PRAC Rapporteur Assessment Report            | 25 November 2024 |
| PRAC Outcome                                         | 28 November 2024 |
| CHMP members comments                                | 2 December 2024  |
| Updated CHMP Rapporteur Assessment Report            | 6 December 2024  |
| 2 nd Request for supplementary information (RSI)     | 12 December 2024 |
| CHMP Rapporteur Assessment Report                    | 25 March 2025    |
| PRAC Rapporteur Assessment Report                    | 27 March 2025    |
| PRAC members comments                                | 02 April 2025    |
| Updated PRAC Rapporteur Assessment Report            | 3 April 2025     |
| PRAC Outcome                                         | 10 April 2025    |
| CHMP members comments                                | 14 April 2025    |
| Updated CHMP Rapporteur Assessment Report            | 16 April 2025    |
| Opinion                                              | 25 April 2025    |

## 2. Scientific discussion

## 2.1. Introduction

Remdesivir (RDV, GS-5734) is a single diastereomer, monophosphoramidate prodrug of a nucleoside analogue that is intracellularly metabolised into an analogue of adenosine triphosphate that inhibits viral RNA polymerases.

<div style=\"page-break-after: always\"></div>

Interim data from the Phase 2/3 Study GS-US-540-5823 (Cohorts 1 to 4, and Cohort 8), evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of RDV for paediatric participants at least 28 days of age and older weighing at least 3 kg. The data from Cohorts 1 to 4, and Cohort 8 together with data  from  3  Phase  3  studies  (GS-US-540-5773,  GS-US-540-5774,  and  CO-US-540-5776  [National Institute of  Allergy  and  Infectious  Diseases-sponsored Adaptive COVID-19 Treatment Trial-1; NIAID ACTT-1]) in adults and adolescents hospitalised with COVID-19 infection, as well as from Study GS-US540-9012 in non-hospitalised adults and adolescents, supported the use of RDV for the treatment of COVID-19.

Veklury, which contains the active substance remdesivir, showed a clinically meaningful effect on time to recovery in adult and adolescent COVID-19 patients with pneumonia requiring supplemental oxygen, while being well tolerated with mild side effects. Veklury was also effective in preventing hospitalisation in adult and adolescent patients who did not need supplemental oxygen and who were at high-risk of developing severe COVID-19. Veklury was shown to be absorbed, modified and removed from the body in a similar way in children, as it is in adults; side effects observed in children were also shown to be comparable to those seen in adults.

Based on the above interim data, Veklury was approved in the European Union on 3 July 2020. At the time of submission of this application, it was indicated for the treatment of coronavirus disease 2019 (COVID-19) in

- adults  and  paediatric  patients  (at  least  4  weeks  of  age  and  weighing  at  least  3  kg)  with pneumonia  requiring  supplemental  oxygen  (low-  or  high-flow  oxygen  or  other  non-invasive ventilation at start of treatment)
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

## 2.1.1. Problem statement

## Disease or condition

COVID-19 in adult and paediatric populations.

## Epidemiology

As of 28 June 2023, approximately 16.8 million children aged 0 to 17 years in the US had tested positive for COVID-19 since the onset of the pandemic. Although children with COVID-19 frequently have mild or moderate symptoms, COVID-19 can result in severe disease. Children &lt; 1 year old and children with underlying disease are at a higher risk of developing COVID-19-related pneumonia. The cumulative incidence of COVID-19-associated hospitalizations in children aged &lt; 18 years from 1 March 2020 to

17 June 2023 was 202 per 100,000 at Coronavirus Disease 2019-Associated Hospitalization Surveillance Network sites in the US. In total, 14,370 children with COVID-19 were hospitalized from 1 March 2020 to 17 June 2023. Between 01 March 2020 and 30 April 2023, 24.1% (3171/13,140 patients) of children aged 0 to 17 years were admitted to an intensive care unit (ICU), 6.7% (871/13,140 patients) required mechanical ventilation, and 0.6% (77/13,153 patients) died in the hospital.

In Europe, the proportion of weekly reports of cases of COVID-19 infection in children was stable for the period from 17 July 2023 to 23 July 2023. Overall hospital admission rates were also stable over

<div style=\"page-break-after: always\"></div>

the same period. These findings are consistent with the availability of vaccines for adults and children. In those with severe disease, symptoms and radiological findings are similar to those of adults. Furthermore, underlying conditions such as pulmonary disease, immunocompromised state, or coexisting respiratory infections might predispose children to severe respiratory disease. Risk factors identified in children with COVID-19 infection for hospitalization and/or ICU admission include complex chronic diseases, type 1 diabetes, obesity, and cardiac and circulatory congenital anomalies. Prematurity has been identified as a risk factor for severe disease in children under 2 years old.

## Clinical presentation and diagnosis

People with COVID-19 may be asymptomatic or may commonly experience one or more symptoms, including fever, cough, shortness of breath or difficulty breathing, fatigue, myalgia, headache, loss of taste or smell, sore throat, nausea or vomiting, diarrhoea. Children have similar clinical manifestations of COVID-19 to adults, although typically with milder and less frequent symptoms, and significantly lower rates of severe disease and death. The clinical findings overlap with those of multiple other clinical syndromes (e.g. pneumonia, bronchiolitis, gastroenteritis and common febrile illnesses) with fever or chills and cough being the most common reported symptoms. Infants may have difficulty feeding and fever without an obvious source. As in adults, children with underlying medical conditions are at risk for severe disease, and chronic pulmonary disease (including asthma), obesity, neurological and developmental conditions, cardiovascular disease and immunosuppression conditions are the most frequently reported risk factors. Severe disease in children is associated with: elevated inflammatory markers (e.g. CRP, procalcitonin, interleukin 6, ferritin, D-dimer) at admission or during hospitalization; dyspnoea, tachypnoea, and/or hypoxia at admission; and gastrointestinal symptoms (WHO; Clinical management of COVID-19, Guideline 18 August 2023). Nucleic acid amplification tests are the reference method for detection of current SARS-CoV-2 infection (WHO, Diagnostic testing for SARS-CoV-2 infection, 2022).

## Management

In the EU, vaccines against SARS-CoV-2 infection are approved, as well as antiviral treatment in adult and paediatric patients.

In addition, patients with COVID-19 are treated with relevant supportive care, including e.g., oxygen, mechanical ventilation and other life support, as required.

## Claimed therapeutic indication

With this application, the MAH initially proposed to extend the indication to include the treatment of COVID-19 in paediatric patients from birth weighing at least 1.5 kg, based on the PK, efficacy, and safety data from the final analysis of the Phase 2/3 Study GS-US-540-5823. In practice, the MAH initial proposal for the extended indications was:

Veklury isindicated for thetreatmentofcoronavirus disease2019 (COViD-19) in adults andpaediatric patients (weighing at least 1.5 kg):

- adults and paediatric patients (atleast 4 weeksof age and weighing at least3kg)withpneumonia requiring supplemental oxygen (low-orhigh-flow oxygen or other non-invasive ventilation at start of treatment)
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who areatincreased riskofprogressingtosevereCoviD-19

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Remdesivir is a nucleotide prodrug that is intracellularly metabolized into an analogue of adenosine triphosphate that inhibits viral RNA polymerases. Remdesivir competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV 2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA. Remdesivir triphosphate can also inhibit viral RNA synthesis following its incorporation into the template viral RNA by compromising the efficiency of incorporation of the complementary natural nucleotide. Remdesivir has broadspectrum activity against members of the coronaviruses (CoVs; e.g., severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2], SARS-CoV, Middle East respiratory syndrome [MERS]-CoV), filoviruses (e.g., Ebola virus, Marburg virus), and paramyxoviruses (e.g., respiratory syncytial virus [RSV], Nipah virus, Hendra virus).

## 2.1.3. The development programme

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Ltd. submitted to the European Medicines Agency on 29 May 2023 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0201/2020 issued on 19 May 2020, the decision P/0060/2021 issued on 5 February 2021, the decision P/0338/2021 issued on 9 August 2021 and the decision P/0221/2022 issued on 24 June 2022. This application for modification was accepted (EMEA-002826-PIP01-20-M04). The modification related to the key binding element for evaluable participants in cohort 5 of the GS-US-540-5823 study. As only three participants in cohort 5 were treated (one consent was withdrawn before the first dose) and therefore evaluable for PK and safety, the number of evaluable participants in cohort 5 was revised from four to three.

## 2.1.4. General comments on compliance with GCP

The MAH provided statements that clinical trials were conducted in accordance with GCP.

## 2.2. Non-clinical aspects

No new non-clinical data were submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No new ecotoxicity data were provided, as the extended indication would not lead to a significant increase in environmental exposure through the use of remdesivir or the environmentally relevant API GS-441524, which was considered acceptable by the CHMP.

## 2.2.2. Conclusion on the non-clinical aspects

Remdesivir or the environmentally relevant API GS-441524 are not expected to pose a risk to the environment as a result of the extended indication.

Veklury should be used according to the precautions stated in the SmPC in order to minimise any potential risks to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

The proposals for extending the indications of Veklury are based on final results from study GS-US540-5823 (the Phase 2/3 single-arm, open-label study to evaluate the  safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to &lt; 18 years of age with COVID-19 which constituted the basis of the initial MAA) and a PopPK model to evaluate the PK of remdesivir and its metabolites (GS-704277 and GS-441524).

## GCP

The Clinical trial GS-US-540-5823 was performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.3.2. Pharmacokinetics

## Absorption, Distribution, Elimination

No new information was submitted by the MAH. The disposition properties (i.e., absorption, distribution, metabolism, and elimination) of RDV and its metabolites (GS-704277 and GS-441524) have been previously characterized in adults and nonclinical studies. The underlying disposition pathways in paediatric participants are consistent with those in adults.

## Effect of Intrinsic Factors

Population pharmacokinetic (PopPK) analyses were used to examine the effect of intrinsic factors of interest  (e.g.,  body  weight,  age,  renal  function,  hepatic  function,  demographic  factors,  and  disease severity/status) on the PK of RDV and its metabolites in paediatric participants from birth to less than 18 years of age and weighing at least 1.5 kg in Study GS-US-540-5823.

## Effect of Extrinsic Factors

No new information was submitted by the MAH. Drug-drug interaction recommendations for RDV based upon clinical results in adults may be extrapolated to the paediatric population.

## Pharmacokinetics of SBECD

Plasma  exposures  of  the  excipient  sulfobutylether β -cyclodextrin  sodium  (SBECD)  following  IV  RDV administration in paediatric participants from birth to less than 18 years of age were comparable to those in adult participants with normal renal function. SBECD PK data in paediatric participants less than 2 years of age were very limited but appeared consistent with those in paediatric participants at least 2 years of age.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics of RDV and its Metabolites

The PK of RDV and its metabolites following IV RDV administered at a 200-mg loading dose followed by 100-mg daily maintenance doses (Cohorts 1 and 8), 5-mg/kg loading dose followed by 2.5-mg/kg daily maintenance  doses  (Cohorts  2  to  5),  or  2.5-mg/kg  loading  dose  followed  by  1.25-mg/kg  daily maintenance doses (Cohorts 6 and 7) in paediatric participants with COVID-19 are summarized in Table 1.

Evaluation of the PK of RDV and its metabolites (GS-704277 and GS-441524) was conducted using a PopPK model (CTRA-2023-1076 RDV PopPK). Higher exposures (AUCtau) of metabolites GS-704277 and GS-441524, but not RDV, were observed in Cohorts 5 to 7 compared with older paediatric cohorts; however, interpretation is limited due to the small sample size.

Given the limited data in Cohorts 5 to 7 in Study GS-US-540-5823, simulations of virtual populations were performed to characterize the range of PK exposures in paediatric participants of the age and weight ranges associated with these cohorts.

There was an overall trend toward increased AUCtau, Cmax, and Ctau (GS-441524 only) in Cohorts 5 to 7 at the RDV doses administered when compared to adults with COVID-19 in Phase 3 studies; however, interpretation is limited given the small sample size (n = 5) in Study GS-US-540-5823 (Figure 1 for RDV, Figure 2 for GS-704277 and Figure 3 for GS-441524).

Table 1 GS-US-540-5823: Mean (%CV) Population PK Model-Predicted, Steady-State Exposures for RDV, GS-704277, and GS-441524 in Paediatric Patients With COVID-19

| Analyte/ PK Parameter   | Cohort l: Age 12 to <18 Year's and Weight ≥40 kg N=12   | Cohort 2: Age 28 Days to<18 Year's and Weight 20 to<40 kg N=12   | Cohort 3: Age 28 Days to <18 Years and Weight 12 to <20 kg N=11   | Cohort 4: Age 28 Days to <18Years and Weight 3 to<12 kg N=10   | Cohort 5: Age14to<28 Days, GA >37 Weeks,and Weight≥2.5 kg N=3   | Cohort 6: Age <14 Days, GA>37 Weeks, and Birth Weight≥2.5kg N=1   | Cohort 7: Age<56 Days, GA≤37Weeks, and Birth Weight≥1.5 kg N=1   | Cohort 8: Age <12 Year's and Weight ≥40 kg N=5   | Total N=55     |
|-------------------------|---------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------------------------|----------------|
| RDV                     |                                                         |                                                                  |                                                                   |                                                                |                                                                 |                                                                   |                                                                  |                                                  |                |
| Cmax (ng/mL)            | 4108.7 (33.2)                                           | 6003.5 (31.3)                                                    | 5980.1 (38.2)                                                     | 5192.9 (39.8)                                                  | 4829.0 (19.8)                                                   | 7143.8                                                            | 4395.9                                                           | 4235.7 (42.3)                                    | 5204.7 (37.2)  |
| AUCau (h-ng/mL)         | 2630.1 (35.1)                                           | 3937.9 (50.3)                                                    | 6752.1 (161.6)                                                    | 3625.7 (92.7)                                                  | 2650.3 (22.2)                                                   | 4320.7                                                            | 2390.2                                                           | 2519.6 (49.0)                                    | 3938.3 (132.8) |
| GS-704277               |                                                         |                                                                  |                                                                   |                                                                |                                                                 |                                                                   |                                                                  |                                                  |                |
| Cmax (ng/mL)            | 360.6 (57.7)                                            | 469.0 (51.1)                                                     | 484.8 (50.3)                                                      | 407.8 (32.5)                                                   | 466.0 (23.8)                                                    | 547.7                                                             | 642.0                                                            | 297.9 (53.8)                                     | 426.2 (47.9)   |
| AUCau (h·ng/mL)         | 1222.9 (110.2)                                          | 860.3 (59.6)                                                     | 876.0 (82.2)                                                      | 776.0 (62.5)                                                   | 1049.0 (24.2)                                                   | 1264.1                                                            | 1126.5                                                           | 671.4 (82.4)                                     | 932.6 (84.4)   |
| GS-441524               |                                                         |                                                                  |                                                                   |                                                                |                                                                 |                                                                   |                                                                  |                                                  |                |
| Cmax (ng/mL)            | 276.4 (118.4)                                           | 210.5 (57.5)                                                     | 186.5 (55.3)                                                      | 209.8 (23.7)                                                   | 371.8 (40.6)                                                    | 246.5                                                             | 363.0                                                            | 230.4 (110.7)                                    | 234.0 (80.3)   |
| AUCau (h·ng/mL)         | 5486.2 (138.5)                                          | 3016.1 (80.4)                                                    | 2751.8 (67.9)                                                     | 2969.1 (31.7)                                                  | 6899.3 (56.7)                                                   | 3726.1                                                            | 7005.4                                                           | 4336.8 (131.3)                                   | 3910.9 (110.2) |
| Cau (ng/mL)             | 146.7 (125.9)                                           | 83.3 (89.9)                                                      | 81.9 (77.3)                                                       | 86.0 (42.6)                                                    | 193.4 (46.7)                                                    | 119.7                                                             | 196.2                                                            | 117.1 (122.3)                                    | 109.1 (100.9)  |

%CV = percentage coeficient of variation; GA = gestational age; PK = pharmacokinetic(s); RDV = remdesivir.

bythePKlaboratoryforRDV.

The PK parameters from Study GS-US-540-5823 were simulated using population PK modeling with 30 minutes of duration for RDV infusions.

TheGS-US-540-5823MetabolitesPKAnalysisSetincludes allenrolledparticipantswhoreceivedatleast1doseofRDVandhadatleast1nonmissingPKconcentrationdatum reported by the PK laboratory for each respective analyte.

Cohorts1 and8receivedRDV200mgonfirst day(loading dose)followedby100mgdailyforupto10days(steadystate).Cohorts 2to5received RDV5mg/kgonfirst day up to 10 days.

Source:GS-US-540-5823FinalCSR,Tables1.1.1,1.1.2,and 1.1.3

<div style=\"page-break-after: always\"></div>

<!-- image -->

COVID-19 = coronavinus disease 2019; GA = gestational age; PopPK = population phanmacokinetic; RDV = remdesivir whiskers represent 1.5 x the interquartile range. Circles are individual observed values. The dotted lines represent the 5th, 50th, and 95th percentiles in Phase 3 adults (hospitalized, CO-US-540-5844; nonhospitalized,

All exposues in pediatric and adult participants were estimated using the final PopPK model. In Study GS-US-540-5823, Cohont 1 (age 12 to &lt; 18 years, weight ≥ 40 kg) and Cohort 8 (age &lt; 12 years, weight ≥ 40 kg) &lt; 18 years, weight 3 to &lt; 40 kg) received RDV 5 mg/kg on the first day (loading dose) followed by 2.5 mg/kg daily for up to (loading dose) followed by 2.5 mg/kg daily for up to 10 days (steady state); Cohort 6 (age 0 to &lt; 14 days, GA &gt; 37 weeks, weight Cohort 7 (0 to &lt; 56 days, GA ≤ 37 weeks, weight ≥ 1.5 kg) received RDV 2.5 mg/kg on first day (loading dose) followed by (aeps Apeaps) sfep ot o dnioy Aep Eqam gt 1

GS-US-540-9012).

Adults from 2 Phase 3 shudies (hospitalized, C0-US-540-5844; nonhospitalized, GS-US-540-9012) received RDV 200 mg on the first day (loading dose) followed by 100 mg daily (steady state). Source: CTRA-2023-1076 RDV PopPK, Figure 34

Figure 1 Boxplots of Steady-State RDV AUCtau in Paediatric Participants Hospitalised With COVID-19 (GSUS-540-5823) and Phase 3 Adult Participants Hospitalised (CO-US-540-5844) and Nonhospitalised (GSUS-540-9012) With COVID-19

<div style=\"page-break-after: always\"></div>

<!-- image -->

COVID-19 = coronavinus disease 2019; GA = gestational age; PopPK = population pharmacokinetic; RDV = remdesivir whiskers represent 1.5 x the interquartile range. Circles are individual observed values. The dotted lines represent the 5th, 50th, and 95th percentiles in Phase 3 adults (hospitalized, CO-US-540-5844; nonhospitalized,

All exposuwres in pediatric and adult participants were estimated using the final PopPK model.

GS-US-540-9012).

In Shudy GS-US-540-5823, Cohornt 1 (age 12 to &lt; 18 years, weight ≥ 40 kg) and Cohort 8 (age &lt; 12 years, weight ≥ 40 kg) 10 days (steady state); Cohort 5 (age 14 to &lt; 28 days, GA &gt; 37 weeks, weight 2 2.5 kg) received RDV 5 mg/kg on first day Cohort 7 (0 to &lt; 56 days, GA ≤ 37 weeks, weight≥ 1.5 kg) received RDV 2.5 mg/kg on first day (loading dose) followed by *(aleis Apeais) sfep ot ol dn ioy Apep Eqem gt'1

Adults firom 2 Phase 3 studies (hospitalized, CO-US-540-5844; nonhospitalized, GS-US-540-9012) received RDV 200 mg on the (aus Apeais) Auep Em ool Aq pamoog (asop Supeo) Aepisny Source: CTRA-2023-1076 RDV PopPK, Figure 36

Figure 2 Boxplots of Steady-State GS-704277 AUCtau in Paediatric Participants Hospitalised With COVID-19 (GS-US-540-5823) and Phase 3 Adult Participants Hospitalised (CO-US-540-5844) and Nonhospitalised (GS-US-540-9012) With COVID-19

<div style=\"page-break-after: always\"></div>

<!-- image -->

COVID-19 = coronavinus disease 2019; GA = gestational age; PopPK = population phammacokinetic; RDV = remdesivir whiskers represent 1.5 x the interquartile range. Circles are individual observed values. The dotted lines represent the 5th, 50th, and 95th percentiles in Phase 3 adults (hospitalized, C0-US-540-5844; nonhospitalized,

GS-US-540-9012).

All exposuwres in pediatric and adult participants were estimated using the final PopPK model.

In Study GS-US-540-5823, Cohort 1 (age 12 to &lt; 18 years, weight ≥ 40 kg) and Cohort 8 (age &lt; 12 years, weight ≥ 40 kg) 18 years, weight 3 to c 40 kg) received RDV 5 mg/kg on the first day (loading dose) followed by 2.5 mg/kg daily for up to 10 days (steady state); Cohort 5 (age 14 to ≤ 28 days, GA &gt; 37 weeks, weight≥ 2.5 kg) received RDV 5 mg/kg on first day (loading dose) followed by 2.5 mg/kg daily for up to 10 days (steady state); Cohort 6 (age 0 to &lt; 14 days, GA &gt; 37 weeks, weight (aeis Apeais) sfep o1 oi dn ioy 4lrep Ex/am gz 1

Adults from 2 Phase 3 studies (hospitalized, CO-US-540-5844; nonhospitalized, GS-US-540-9012) received RDV 200 mg on the

Source: CTRA-2023-1076RDV PopPK, Figuwe 38

Figure 3 Boxplots of Steady-State GS-441524 AUCtau in Paediatric Participants Hospitalised With COVID-19 and Phase 3 Adult Participants Hospitalised (CO-US-540-5844) and Nonhospitalised (GS-US540-9012) With COVID-19

Hospitalisation was identified as a statistically significant covariate for clearance of GS-704277, but not for RDV or GS-441524, in adults (hospitalized, Study CO-US-540-5844; nonhospitalised, Study GS-US540-9012)  and  in  paediatric  participants  from  birth  to  less  than  18  years  of  age.  As  all  paediatric participants in Study GS-US-540-5823 were hospitalised, the impact of hospitalisation cannot be directly evaluated for paediatric participants. Thus, the effect of hospitalisation in paediatric participants was assumed to be the same as adults and evaluated using virtual populations for each paediatric cohort (600  virtual  individuals  per  group,  which  was  deemed  to  be  a  suitably  large  sample  size).  Virtual populations used for simulations were created based on age and weight distributions from paediatric growth charts ([WHO] growth chart for full-term neonates in Cohorts 4 to 6 {World Health Organization 2023};  Fenton  growth  chart  for  preterm  neonates  in  Cohort  7  {Fenton  2023})  according  to  age, gestational age, and weight specifications as per the study protocol. Geometric mean ratio (GMR) values for RDV and GS-441524 exposures in hospitalised versus nonhospitalised paediatric participants were 0.859 to 1.20 for all virtual paediatric cohorts, including neonates (Table 2). The lack of a difference in PK by hospitalisation status is consistent with the lack of a hospitalisation covariate for RDV and GS441524 in the PopPK model for paediatric participants.

<div style=\"page-break-after: always\"></div>

Table 2 Geometric Mean Ratio and 90% CI of Steady-State Exposures for RDV, GS-7024777, and GS441524 Between Nonhospitalised and Hospitalised Populations of Virtual Paediatric Participants With COVID-19

|                    | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   | GMR (90yh CI) of Hospitalized (Test) Versus Nonhospitalized (Reference)   |
|--------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Anshyte PK Paramet | Virtual Cohortl (200/100 m N=600                                          | Virtual Cohort 2 (5/2.5 mg/k N=600                                        | Cohort3 (5/2.5 mg/k N=600                                                 | Virthual Cohort 4-up per (5/2.5 mg/kg) N=600                              | Virtual Cohort 4-Ho Wer (5/2.5 gkg) N= 600                                | Virtual Cohort5 (5/2.5 mgl g)N=600                                        | Viriual Cohort 6 (2.51.25 mg kg) N= 600                                   | Virhual Cohort 7 (2.51.25 mg [kg) N= 600                                  |
| RDV                | RDV                                                                       | RDV                                                                       | RDV                                                                       | RDV                                                                       | RDV                                                                       | RDV                                                                       | RDV                                                                       | RDV                                                                       |
|                    | 1.08 (0.954. 1.23)                                                        | 0.975 (0.859, 1.11)                                                       | 1.03 (0.907. 1.17                                                         | 0.924 (0.819, 1.04)                                                       | 0.915 (0.809, 1.04)                                                       | 6160 (0.866, 1.11)                                                        | 1.08 (0.956, 1.21)                                                        | 0560 (0.842, 1.07)                                                        |
| AUC                | 1.20 (1.02, 1.40)                                                         | 6560 (0.826, 1.11)                                                        | 1.04 (0.892, 1.20)                                                        | 0.892 (0.762, 1.04)                                                       | 066'0 (0.793, 1.09)                                                       | 0.957 (0.817. 1.12)                                                       | 1.15 (0.985, 1.35)                                                        | 896'0 (0.830, 1.13)                                                       |
| GS-704277          | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 | GS-704277                                                                 |
|                    | 1.28 (1.13, 1.45)                                                         | 1.23 (1.10, 1.39)                                                         | 1.21 (1.07, 1.37)                                                         | 1.33 (1.18, 1.51)                                                         | 1.16 (1.03, 1.31)                                                         | 1.17 (1.03, 132)                                                          | 1.25 (1.11, 1.41)                                                         | 1.11 (0.988, 1.25)                                                        |
| AUC...             | 1.56 (1.36, 1.77)                                                         | 1.58 (1.38, 1.80)                                                         | 1.43 (1.26, 1.64)                                                         | 1.48 (1.30, 1.69)                                                         | 1.58 (1.39, 1.79)                                                         | 1.39 (1.21, 1.59)                                                         | 1.50 (1.31, 1.72)                                                         | 1.45 (1.26, 1.67)                                                         |
| GS-441524          | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 | GS-441524                                                                 |
|                    | 0.983 (0.910, 1.06)                                                       | 1680 (0.830, 0.957)                                                       | 0.956 (0.886, 1.03)                                                       | 1.00 (0.931, 1.08)                                                        | 0.913 (0.852, 0.979)                                                      | 0.915 (0.847. 0.988)                                                      | 0.947 (0.880, 1.02)                                                       | 0.859 (0.797, 0.927)                                                      |
| AUC....            | 1.03 (0.948. 1.11)                                                        | 5560 (0.884, 1.03)                                                        | 0.983 (0.909, 1.06)                                                       | 1.02 (0.943, 1.10)                                                        | 0.983 (0.910, 1.06)                                                       | 0.927 (0.856. 1.00)                                                       | 0.972 (0.901, 1.05)                                                       | 0.916 (0.847, 0.992)                                                      |
|                    | 1.07 (0.974. 1.18)                                                        | 1.01 (0.912. 1.12)                                                        | 0.987 (0.889, 1.10)                                                       | 1.00 (0.889, 1.13)                                                        | 186'0 (0.884, 1.09)                                                       | 0.878 (0.798. (996'0                                                      | 0.934 (0.854, 1.02)                                                       | 1E6'0 (0.843, 1.03)                                                       |

CI= confidence interval; C0VD-19 = coronavins disease 2019: GA = gestational age: GMR = geomemic mean mtio, PK =phamncokinetic(s): RDV=remdesivir

Vitul Cohort 1 (age 12 to &lt; 18 yeaurs, weight 2 40 kg) received RDV 200 mg on first day (loading dose) followed by 100 mg daily for 5 days (steady siate).

The RDV doses are per protocol for each virtunl pediatic cohort.

Virtul Cohort 2 (age 2 to ≤ 18 years, weight 20 to &lt; 40kg) received RDV 5 mg/kg on first day (loading dose) followed by 2.5 mgkg daily for 5 days (steady state).

Vitul Cohort 4 (age 2 to &lt; 18 years) mas fiuther statified by weight (upper, 7 to &lt; 12 kg: lower, 3 to &lt; 7 kg)andreceived RDV 5 mg/kg on first day (loading dose) followed by 2.5 mg/kg dhily for 5 days (steady state)

s oy Apep aqam gt fq panonoy (asop suprog ep 1sng wo aqam g Not panlaoan (aaot s 01t1 1alan 'sraf g1 s 0it aae) e uoyoo pun days (steady state).

Vitinl Cohort 5 (age 14to &lt; 28 days, GA &gt; 37 weeks, weight ≥ 2.5 kg) received RDV 5 mgkg on first day (loading dose) followed by 2.5 mgkg daily for 5 days (steady state).

Vitul Cohort 6 (age 0 to &lt; 14 days, GA&gt;37 weeks, weight 2 2.5 kg) received RDV 2.5 mg/kg on first day (loading dose) followed by 1.25 mg/kg daily for 5 days (steady state).

mgkg daily for 5 days (stendy state).

Sowce: CTRA-2023-1076 RDV PopPK, Table 14 and Table 15

## Population PK models

The previously developed PopPK model was a sequential model based on 2-compartment models for RDV  and  GS-704277  and  a  3-compartment  model  for  GS-441524  with  first-order  elimination. Adjustment to the paediatric data from Study GS-US-540-5823 was made by inclusion of allometric body weight scaling using fixed allometric exponents: 0.75 for clearance (CL)-related parameters and 1.0 for volume of distribution (V)-related parameters. Given the inclusion of paediatric subjects, a maturation function was incorporated for the CL of RDV and GS-704277 (based on the equation used in Simcyp PBPK software):

<div style=\"page-break-after: always\"></div>

<!-- image -->

Unlike RDV and GS-704277, the major route of elimination for GS-441524 is glomerular filtration; thus, a different renal-specific maturation function was considered:

<!-- image -->

Introduction of these changes allowed for the removal of baseline bilirubin as a significant covariate in the GS-441524 model. No additional covariates were found to significantly impact RDV or GS-441524, but the previous analysis identified baseline ferritin to have a significant impact on GS-704277 in the paediatric population, and this covariate was retained in the model. A covariate search was conducted on the GS-441524 model to verify that including a maturation function did not introduce additional significant covariates. For the adult population, age &gt;60 years was kept as a categorical covariate on GS-441524 and GS-704277 as in the previous model. Hospitalized subjects with COVID-19, adult and paediatric, had a lower CL (31.8% decrease) of GS-704277. Given the lack of data for nonhospitalised paediatric  subjects  with  COVID-19,  it  was  assumed  that  the  effect  of  hospitalisation  was  the  same between adult and paediatric subjects. Within the paediatric population, baseline ferritin was found to impact the CL (15.1% decrease) of GS-704277. The final model implemented an M6 method for handling BLQ samples.

## Data

Overall, 11518 samples were used in the PopPK analysis, of which 10849 were adult PK samples and 669 were paediatric PK samples (180 from adolescents, 465 from subjects &gt;28 days old, and 24 from subjects ≤28 days old). By gestational age, 29 samples came from preterm subjects (GA ≤37 weeks). By patient status, 4640 were samples from subjects with COVID-19 and 6878 were samples from healthy subjects (who were all adults).  Neonatal cohorts were as follows (including dosing regimen applied in the study):

Table 3. Definition of Cohorts 5, 6, and 7 and Dosing Regimen Applied in Study  -5823 Tem neonatal subjects 0 to &lt;28 days

<!-- image -->

|                                         | 214 to <28 days of age, GA >37 weeks. and weight at Screening 22.5 kg   | IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily for up to 10 days    |
|-----------------------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 6                                       | 0 to <.14 days of age. GA >37 weeks, and birth weight ≥2.5 kg           | IV RDV 2.5 mg/kg on Day 1 followed by IV RDV 1.25 mg/kg daily for up to 10 days |
| Preterm neonatal subjects 0 to <56 days | Preterm neonatal subjects 0 to <56 days                                 | Preterm neonatal subjects 0 to <56 days                                         |
|                                         | 0 to <56 days of age. GA ≤37 weeks,and bith weight ≥1.5 kg              | IV RDV 2.5 mg/kg on Day 1 followed by IV RDV 1.25 mg/kg daily for up to 10 days |

In cohort 5, three patients were evaluated, and one patient was included in each of cohorts 6 and 7.

The parameters of the final model are shown in Table 4.

<div style=\"page-break-after: always\"></div>

Table 4. Summary of Sequential Final Model PK Parameters for RDV, GS-704277, and GS-441524

| Parameter - Model   | Parameter Description                                              |   Population Estimate |   %RSE |
|---------------------|--------------------------------------------------------------------|-----------------------|--------|
| 01 - remdesivir     | CL - remdesivir (L/h)                                              |                50.4   |  2.56  |
| 02 - remdesivir     | Central volume - remdesivir (L)                                    |                 7.01  |  0.443 |
| 03 - remdesivir     | Peripheral volume - remdesivir (L)                                 |                 6.42  |  0.259 |
| 04-remdesivir       | Intercompartmental clearance - remdesivir (L/h)                    |                 5.16  |  3.67  |
| θ-GS-704277         | CL - GS-704277 (L/h)                                               |               292     |  5.08  |
| θ2 - GS-704277      | Central volume - GS-704277 (L)                                     |               285     |  6     |
| 03 -GS-704277       | Peripheral volume - GS-704277 (L)                                  |               143     | 34.8   |
| 04-GS-704277        | Intercompartmental clearance - GS-704277 (L/h)                     |                11.3   | 12.5   |
| θ-GS-704277         | Effect of baseline ferritin for pediatric subjects on clearance    |                -0.151 | 61     |
| θg-GS-704277        | Effect of hospitalization for subjects on clearance                |                -0.318 | 19.7   |
| θg-GS-704277        | Effect of age for subjects 60 years or older on central volume     |                -0.24  | 29.4   |
| θ1 -GS-441524       | Clearance - GS-441524 (L/h)                                        |                26.2   |  2.99  |
| 02-GS-441524        | Central volume - GS-441524 (L)                                     |               139     |  5.65  |
| 0 -GS-441524        | First peripheral volume - GS-441524 (L)                            |               373     |  4.03  |
| 04 -GS-441524       | Intercompartmental clearance to first periph. cmt. GS-441524 (L/h) |               537     |  4.89  |
| 05-GS-441524        | Second peripheral volume - GS-441524 (L)                           |               292     |  5.87  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Parameter - Ppon      | Parameter Description                                               | Population Estimate   |   96RSE |
|-----------------------|---------------------------------------------------------------------|-----------------------|---------|
| 86- GS-441524         | Intercompartmental clearance to second periph. cmt. GS-441524 (L/h) | 45.6                  |  6.61   |
| 8g - GS-441524        | Effect of age for subjects 60 years or older on clearance           | -0.35                 | 10.4    |
| 0'11 - remdesivir     | IIV of CL - remdesivir, Phases 1 and 2/3 (%CV)                      | 42.8%                 | 16.7    |
| 0²2 -remdesivir       | IIV of V1 - remdesivir, Phases 1 and 2/3 (%CV)                      | 39.6%                 | 38.3    |
| 0'ss - remdesivir     | IIV of CL - remdesivir, Phase 3 (%CV)                               | 152%                  |  5      |
| 0²4 - remdesivir      | IIV of V1 - remdesivir, Phase 3 (%CV)                               | 314%                  | 61.9    |
| 0'1 - GS- 704277      | IIV of CL-GS-704277, Phases 1 and 2/3 (%CV)                         | 45.4%                 |  9.57   |
| 0²2 - GS- 704277      | IIV of V1 -GS-704277, Phases 1 and 2/3 (%CV)                        | 56%                   | 12.5    |
| 00²33 - GS- 704277    | IIV of CL-GS-704277, Phase 3 (%CV)                                  | 122%                  | 13.7    |
| 0²4 - GS- 704277      | IIV of V1 -GS-704277, Phase 3 (%CV)                                 | 149%                  | 11.8    |
| 0²11 - GS- 441524     | IIV of CL-GS-441524, Phases 1 and 2/3 (%6CV)                        | 51.5%                 | 12      |
| 0² - GS- 441524       | IIV of V1 -GS-441524, Phases 1 and 2/3 (%%CV)                       | 90.9%                 |  9.2    |
| 00's3 - GS- 441524    | IIV of Vp1-GS-441524, Phases 1 and 2/3 (%CV)                        | 54.8%                 | 10.1    |
| 0²44 - GS- 441524     | IIV of Vp2-GS-441524, Phases 1 and 2/3 (%CV)                        | 62.4%                 | 21.1    |
| 0²ss - GS- 441524     | IIV of CL-GS-441524, Phase 3 (%CV)                                  | 66.3%                 |  8.77   |
| 00²6 - GS- 441524     | IIV of V1 -GS-441524, Phase 3 (%CV)                                 | 159%                  | 11.1    |
| 0², - GS- 441524      | IIV of Vp1-GS-441524, Phase 3 (%CV)                                 | 182%                  | 11.2    |
| ∞²ss - GS- 441524     | IIV of Vp2-GS-441524, Phase 3 (%CV)                                 | 244%                  | 10.2    |
| 01 - remdesivir       | Variance of residial error - remdesivir, Phases 1 and 2/3           | 0.593                 | 10.5    |
| O - remdesivir        | Variance of residial error - remdesivir, Phase 3                    | 1.75                  |  0.0262 |
| 01 - GS-704277        | Variance of residual error - GS-704277, Phases 1 and 2/3            | 0.158                 | 42.9    |
| 02 - GS-704277        | Variance of residual error - GS-704277, Phase 3                     | 1.21                  | 47.1    |
| 01 - GS-441524        | Variance of residual error - GS-441524, Phases 1 and 2/3            | 0.225                 | 22.7    |
| 0- GS-441524          | Variance of residual error - GS-441524, Phase 3                     | 0.907                 | 27.8    |
| sqit(θs) - remdesivir | Proportional residual error - remdesivir (%CV)                      | 40.6%                 |  0.142  |
| O6 - remdesivir       | Additive residual error - remdesivir (ng/mL)                        | 1.8                   |  0.428  |
| sqrt(es) - GS- 704277 | Proportional residual error - GS-704277 (%CV)                       | 65%                   | 24      |

<div style=\"page-break-after: always\"></div>

| Parameter' - Model    | Paraimeter Description                        | Population Estimate   | 96RSE   |
|-----------------------|-----------------------------------------------|-----------------------|---------|
| θ6- GS-704277         | Additive residual error - GS-704277 (ng/mL)   | 1                     |         |
| sqit(e,) - GS- 441524 | Proportional residual error - GS-441524 (%CV) | 22.3%                 | 13.1    |
| 8s - GS-441524        | Additive residual error - GS-441524 (ng/mL)   | 1                     |         |

%CV = percentage of the coefficient of variation; %RSE = percentage of the relative standard error; θ = absolute value of the estimate; o = variance of residual error; o = interindividual variability; CL = clearance;

IIV = interindividual variability; OFV = objective fiunction value; periph. cmt. = peripheral compartment; PK = pharmacokinetic(s); RDV = remdesivir; V1 = central volume of distribution; Vp1 = first peripheral volume of distribution; Vp2 = second peripheral volume of distribution.

OFV -remdesivir =25333.8809,OFV -GS-704277=23830.4336,and 0FV -GS-441524=28357.3737.

Condition mumber -Remdesivir = 6.891e7, Condition mumber-GS-704277 = 750.7, and Condition number GS-441524 = 106.3.

Additive residual error was fixed to 1 ng/mL for the GS-704277 and GS-441524 models. Source: RDV-Diagnostics\\_v2.html, M1-Diagnostics\\_v2.html, M2-Diagnostics\\_v2.html

## Model evaluation

The VPCs for metabolite GS-441524 for the different age groups is shown in Figure 4 below.

<div style=\"page-break-after: always\"></div>

BLQ = below the limit of quantitation; CI = confidence interval; VPC = visual predictive check. Source: VPC\\_all\\_models\\_v5.html

<!-- image -->

Figure 4 Dose-Normalized VPC Stratified by Age of the Final GS-441524 Model

## Simulations

Simulations using the final PopPK model were performed for neonate cohorts of interest generated from relevant growth charts (Adults and Cohorts 1 to 3 and 8 from the NHANES growth chart; Cohorts 4 to 6 from the WHO growth chart; and Cohort 7 from the Fenton Preterm growth chart) following the dosing regimens per protocol. N = 600 virtual subjects were generated for each of the cohorts of interest according to the demographics specified in the enrolment criteria, with an equal distribution of males and females and an equal distribution of hospitalized and nonhospitalised subjects. Based on the initial results, additional simulations were conducted to explore dose alignment of Cohort 5 with the 2.5 mg/kg loading dose and the 1.25 mg/kg once-daily maintenance dose administered as IV infusion over 0.5 hours. The results of these simulations showed similar exposures in the virtual Cohorts 5 to 7 with the 2.5 mg/kg loading dose and the 1.25 mg/kg once-daily maintenance dose administered as IV infusion over 0.5 hours with the adult COVID-19 patient exposures. The cohorts of interest were as follows (virtual Cohorts 5 to 7 were as defined in Study GS-US-540-5823):

- Virtual Cohort 5: ≥14 days to &lt;28 days of age, GA &gt;37 weeks, and weight at screening ≥2.5 kg
- Virtual Cohort 6: 0 days to &lt;14 days of age, GA &gt;37 weeks, and birth weight ≥2.5 kg

<div style=\"page-break-after: always\"></div>

- Virtual Cohort 7: 0 days to &lt;56 days of age, GA ≤37 weeks, and birth weight ≥1.5 kg
- Virtual neonates: 0 days to &lt;56 days of age, half population GA ≤37 weeks and half population GA &gt;37 weeks, and birth weight ≥1.5 kg

<!-- image -->

AUC= area under the concentration-time curve; C =Cohort. The lower, middle, and upper bars of the boxplot represent the 25th, 50th, and 75th percentiles, respectively. The upper and lower whiskers represent 1.5x the interquartile range. Dotted lines represent the 5th, 50th, and 95th percentiles in Phase 3 adults (hospitalized, CO-US-540-5844; nonhospitalized, GS-US-540-9012). See Table 31 for specific exposure values. See Table 11 for cohort age, weight, and dosing information. Source:Simulations\\_v10.html

Figure 5 Boxplot of Simulated GS-441524 AUC in Virtual Neonate Cohorts and Adults

## Discussion on pharmacokinetics

With this submission, the MAH provided pharmacokinetic data to support the extension of the indication to include paediatric patients from birth weighing 1.5 kg to &lt;3 kg with pneumonia requiring supplemental oxygen and paediatric patients weighing 1.5 kg to &lt; 40 kg not requiring supplemental oxygen but are at  increased  risk  of  progression  to  severe  COVID-19.  Evaluation  of  the  PK  data  for  RDV  and  its metabolites showed a higher exposure (AUCtau) for the metabolites but not for RDV. However, the limited number of participants in cohorts 5 to 7 (n=5) limits the interpretation of these data. Therefore, virtual population  simulations  were  performed  to  explore  PK  exposures  in  the  paediatric  participants  using parameters appropriate for participants in cohorts 5 to 7. Using virtual populations of neonates and preterm neonates and infants, the overall range of steady-state exposures simulated by the PopPK model (AUCtau and Cmax; Ctau only for GS-445124) of RDV and its metabolites at the postulated loading and maintenance doses were within the 5 th  and 95 th  percentiles of exposures in hospitalised adult participants with severe COVID-19 pneumonia on supplemental oxygen and in non-hospitalised adult participants with COVID-19 at risk of disease progression and not on supplemental oxygen in Phase 3 studies. As the proposed extension of indication includes paediatric patients from birth weighing at least 1.5 kg who do not require supplemental oxygen but are at increased risk of progression to severe COVID-19, data from this paediatric patient population should be evaluated to support the extension of indication. This patient population was not included in cohorts 5 to 7 of the GS-US-540-5823 study. Therefore, an analysis of

<div style=\"page-break-after: always\"></div>

intrinsic factors including body weight, age, renal and hepatic function, demographic factors, disease status and hospitalisation status was performed for paediatric participants from birth to 18 years of age and weighing ≥ 1.5 kg. Such an analysis has alr eady been carried out for the interim analysis of this study. Details of the effect of intrinsic factors are discussed below.

Body weight was the most significant covariate affecting the PK of RDV and its metabolites in paediatric participants. Baseline ferritin levels (a marker of COVID-19 disease severity) had a small impact on the PK of GS-704277 within the paediatric population; however, the clinical relevance is unknown as this covariate was only identified in paediatric participants. Overall, there was no consistent trend in study GS-US-540-5823 (all  cohorts)  of  increased  or  decreased  exposures  across  body  weight  quartiles  in paediatric participants who received a weight-based dose.

Renal  function  by  estimated  glomerular  filtration  rate  (eGFR)  was  not  identified  as  a  statistically significant covariate for RDV and its metabolites in paediatric participants.

Hepatic function by baseline alanine aminotransferase (ALT) and baseline aspartate aminotransferase (AST) was not identified as a statistically significant covariate for RDV and its metabolites in paediatric participants.

Sex,  race,  and  ethnicity  were  not  identified  as  statistically  significant  covariates  for  RDV  and  its metabolites in paediatric participants.

Baseline  oxygen  support  status  (i.e.,  whether  supplemental  oxygen  was  required  at  the  start  of treatment)  was  not  identified  as  a  statistically  significant  covariate  for  the  PK  of  RDV  in  paediatric participants from birth to less than 18 years of age (Study GS-US-540-5823). While no comparative data are available for neonates and preterm neonates and infants weighing ≥ 1.5 kg (Cohorts 5 to 7), the MAH was of the opinion that exposures of RDV and its metabolites are not expected to differ by baseline oxygenation  status  in  this  paediatric  age  and  weight  range  based  on  the  lack  of  PK  difference demonstrated in adults and older paediatric participants.

Hospitalisation was identified as a statistically significant covariate for clearance of GS-704277, but not for RDV or GS-441524, in adults and in paediatric participants from birth to less than 18 years of age. Hospitalisation  had  a  modest  impact  on  the  PK  of  GS-704277  that  was  not  considered  clinically meaningful given GS-704277 exposures are expected to be transient based on the short plasma halflife.  As  all  paediatric  participants  in  Study  GS-US-540-5823  were  hospitalised,  the  impact  of hospitalisation cannot be directly evaluated for paediatric participants. Thus, the effect of hospitalisation in paediatric participants was assumed by the MAH to be the same as adults and evaluated using virtual populations for each paediatric cohort. The lack of a difference in PK by hospitalisation status is consistent with the lack of a hospitalisation covariate for RDV and GS-441524 in the PopPK model for paediatric participants.

In conclusion, the results of the analysis of the intrinsic factors showed that the exposures of RDV and its metabolites in paediatric patients do not differ in a clinically relevant way when the baseline oxygen support or the hospitalisation status are taken into account. No other intrinsic factor was identified as a statistically significant covariate for the PK of RDV or its metabolites in paediatric participants from birth to less than 18 years of age.

The developed PopPK model based on adult and paediatric data accounted for weight based changes and included maturation functions to account for changes in the paediatric population from birth to adult age. Overall, diagnostic plots are considered acceptable and precision of parameter estimates overall was in an acceptable range. Moreover, the results of the bootstrap were found to be consistent with the final PopPK estimates for the final models.

<div style=\"page-break-after: always\"></div>

Very limited data were available in the youngest age cohorts in the neonatal period (0-28 days term infants and 0-56 days preterm infants). The adequacy of the doses for neonates (cohorts 5, 6 and 7) was questioned. With the doses initially proposed by the popPK model and investigated in the paediatric study (GS-US-540-5823), the observed data in the neonate cohorts showed that exposure was higher than in adults and older paediatric patients, especially for the most relevant compound GS-441524. The extrapolation approach was aimed at defining doses that lead to same exposures compared to adults and older paediatric patients. Since this aim was not achieved with the doses proposed by the popPK model, the model does not yet adequately describe the PK in the neonate cohort but needed to be refined to better align with the observed data.

The need for refinement of the popPK model might especially concern the maturation of the elimination, but also other factors (e.g. total body water, body composition (adipose tissue portion), specific enzyme functions) might need to be considered. Subsequently, sensitivity analyses with respect to dose selection and VPCs were requested to be conducted for the refined model focussing on the age and weight ranges impacted by the proposed variation, also including the specific age range preterm population.

As requested, the MAH evaluated modifications to the paediatric model and presented a modified model. However, the new popPK model presented was still not considered to improve the fit to the data. In summary, the MAH provided two different popPK models in order to adequately characterise the PK of paediatric patients down to birth. Neither model was however capable to accurately characterise the clearance of the most relevant compound GS-441524. It was considered that the database was too limited to be able to develop a reliable model to characterise the PK down to birth and robust enough to allow  for  simulations.  As  none  of  the  popPK  models  were  considered  sufficient,  no  dose  could  be recommended  for  paediatric  patients  from  birth  onwards  to  four  weeks  of  age  and  below  3  kg bodyweight, as represented by cohorts 5, 6 and 7.

## 2.3.3. Pharmacodynamics

No trends were identified between exposures of RDV and its metabolites and the efficacy endpoints evaluated in paediatric participants from birth to less than 18 years of age in Study GS-US-540-5823. There were no significant differences in exposures of RDV and its metabolites in those with and without each of the 9 most common adverse events (AEs), although interpretation is limited due to the low incidence of these AEs in Study GS-US-540-5823.

## 2.4. Clinical efficacy

## 2.4.1. Main study: GS-US-540-5823 (CARAVAN)

## Methods

## Study design

Study GS-US-540-5823 is a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir (GS-5734™) in participants from birth to &lt; 18 years of age with COVID-19. The study was planned with 22 study centres in Italy, Spain, the United Kingdom, and the United States. Cohorts 5 to 7 from Study GS-US-540-5823 are included in this submission (Table 5).

<div style=\"page-break-after: always\"></div>

Table 5. Clinical Study Providing Data for the RDV Clinical Program in the Paediatric Population

|                 | Study Design                                                                                                                   | Participant Population   | Participant Population                                                                   | Treatment Regimens                                                                                                                         | N   | Location of Summary                                            |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------|
| Study Number    |                                                                                                                                | Cohort                   | Age/Weight Group                                                                         |                                                                                                                                            |     |                                                                |
| GS-US-540-5823a | A Phase 2/3 single-arm, open-label study to evaluate RDV in participants < 18 years of age with laboratory- confirmed COVID-19 | 5                        | ≥14 days to < 28 days of age, gestational age > 37 weeks, and weight at screening ≥2.5kg | IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily for up to 10 days IV RDV 2.5 mg/kg on Day 1 followed by IV RDV 1.25 mg/kg daily | 3   | CSR: GS-US-540-5823 Final CSR Narrative: m2.7.4, Section 1.2.1 |
| GS-US-540-5823a | A Phase 2/3 single-arm, open-label study to evaluate RDV in participants < 18 years of age with laboratory- confirmed COVID-19 | 6                        | 0 days to < 14 days of age, gestational age > 37 weeks, and birth weight ≥ 2.5 kg        | for up to 10 days                                                                                                                          | 1   | CSR: GS-US-540-5823 Final CSR Narrative: m2.7.4, Section 1.2.1 |
| GS-US-540-5823a | A Phase 2/3 single-arm, open-label study to evaluate RDV in participants < 18 years of age with laboratory- confirmed COVID-19 | 7                        | 0 days to < 56 days of age, gestational age ≤ 37 weeks, and birth weight≥1.5 kg          | for up to 10 days                                                                                                                          | 1   | CSR: GS-US-540-5823 Final CSR Narrative: m2.7.4, Section 1.2.1 |

COVID-19 = coronavinus disease 2019; CSR = clinical study report; IV = intravenous; RDV = femdesivir; N = number of participants treated

- a Results from Cohorts 5 to 7 are the focus of this submission

## Main inclusion criteria:

Children  and  adolescents  &lt;  18  years  who  had  SARS-CoV-2  infection  confirmed  by  PCR,  who  were hospitalised and required medical care for COVID-19, and had the following body weight criteria were included:

- Weight at screening ≥ 2.5 kg for ≥ 14 days to &lt; 28 days of age or gestational age &gt; 37 weeks
- Birth weight ≥ 2.5 kg for 0 days to &lt; 14 days of age/gestational age &gt; 37 weeks
- Birth weight ≥ 1.5 kg for 0 days to &lt; 56 days of age/gestational age ≤ 37 weeks

## Study participants

It was planned to enrol at least 4 participants in Cohort 5, and no minimum was calculated for Cohorts 6 and 7. Of the 6 participants screened; 4 participants enrolled in Cohort 5, 1 participant in Cohort 6, and 1 participant in Cohort 7. One participant in Cohort 5 enrolled but did not receive treatment due to withdrawal of consent by the parents. Another participant in Cohort 5 discontinued study drug on Day 9 at the investigator's discretion due to clinical improvement.

## Treatments

In this study, dose selection of RDV to be evaluated in paediatric participants targeted similar exposures to those observed in adults. Dose selection for participants in Cohort 5 was informed by a physiologically based  pharmacokinetic  (PBPK)  model  developed  to  characterize  the  PK  of  RDV  and  the  primary circulating nucleoside metabolite, GS-441524, in adults (SimCYP Version 17, Certara). For dose selection in Cohorts 6 and 7, a population pharmacokinetic (PopPK) model was used (with data from Cohorts 1 to 4 and Cohort 8 and 1 participant in Cohort 5) to predict paediatric patient exposures.

For participants in Cohort 5 (≥ 14 days to &lt; 28 days of age, gestational age &gt; 37 weeks, and weight at screening ≥ 2.5 kg) an RDV loading dose of 5 mg/kg followed by 2.5 mg/kg once -daily maintenance dose of RDV was selected and subsequently evaluated in the study. For participants in Cohort 6 (0 days

<div style=\"page-break-after: always\"></div>

to &lt; 14 days of age, gestational age &gt; 37 weeks, and birth weight ≥ 2.5 kg) and Cohort 7 (0 days to &lt; 56 days of age, gestational age ≤ 37 weeks, and birth weight ≥ 1.5 kg), an RDV loading dose of 2.5 mg/kg followed by 1.25  mg/kg once-daily  maintenance  dose  of  RDV  was  selected  based  on  PopPK modelling and subsequently evaluated in the study. The treatment regimens are described in Table 5.

The duration of treatment was up to 10 days. Participants who demonstrated clinical improvement may have been considered for a shorter treatment period.

## Objectives

The primary objectives were to evaluate the safety and tolerability of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to &lt; 18 years and to evaluate the PK of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to &lt; 18 years. The additional secondary endpoints are related to efficacy and safety (Table 6).

## Outcomes/endpoints

The efficacy endpoints for Study GS-US-540-5823 are similar to those used in the Phase 3 studies (GSUS-540-5773, GS-US-540-5774, and CO-US-540-5776) in the original new drug application (NDA). The PEWS Scale was added as a standard scale that evaluates the risk for clinical deterioration in hospitalized paediatric patients.

<div style=\"page-break-after: always\"></div>

## Study Objectives and Endpoints:

| Primary Objectives                                                                                                                                                                                                                                                         | Primary Endpoints                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| To evaluate the safety and tolerability of remdesivir (RDV, Veklury*) in participants with laboratory-confimed COVID- 19 aged 0 days to < 18 years                                                                                                                         | The proportion of participants with treatment-emergent adverse events The proportion of participants with treatment-emergent graded laboratory abnormalities                                                                      |
| To evaluate the pharmacokinetics (PK) of RDV in paiticipants with laboratory-confirmed COVID-19 aged 0 days to < 18 years                                                                                                                                                  | PK assessed by plasma concentrations of RDV and metabolites                                                                                                                                                                       |
| Secondary Objectives                                                                                                                                                                                                                                                       | Secondary Endpoints                                                                                                                                                                                                               |
| To evaluate the efficacy of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years                                                                                                                                                               | Clinical improvement based on scoring using the 7-point ordinal scale Time (days) to discharge from hospital Days to the first confirmed negative polymerase                                                                      |
| To determine the antiviral activity of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years                                                                                                                                                    | chain feaction (PCR) result, where confirmed is defined as 2 consecutive negative PCR results Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first confirmed negative PCR result (whichever comes first) |
| settings in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years                                                                                                                                                                                      | Change from baseline in the use of mechanical ventilation or extracorporeal membrane oxygenation Clinical improvement based on scoring using                                                                                      |
| To evaluate clinical improvement using the Pediatric Early Warning Score (PEWS) Scale in participants with laboratory-confirmed COVID-19 aged 0 days to < 18 years                                                                                                         | the PEWS Scale                                                                                                                                                                                                                    |
| To support primary objective of evaluating the safety and COVID-19 aged 0 days to < 18 years                                                                                                                                                                               | Bilinubin concentrations in < 14-day-old participants                                                                                                                                                                             |
| To determine sulfobutylether B-cyclodextrin sodium (SBECD) exposures (where possible)                                                                                                                                                                                      | Plasma concentrations of SBECD (where possible)                                                                                                                                                                                   |
| To provide data on use of medications other than RDV for treatment of COVID-19                                                                                                                                                                                             | The proportion of participants with concomitant use of medications other than RDV for treatment of COVID-19                                                                                                                       |
| Exploratory Objectives                                                                                                                                                                                                                                                     | Exploratory Endpoints                                                                                                                                                                                                             |
| Detemine any correlation between reduction in viral shedding and timing and magnitude of immunoglobulin (Ig) response                                                                                                                                                      | Correlationbetween duration of SARS-CoV-2 shedding and timing and amplitude of SARS-CoV-2-specific IgG, IgM, and IgA                                                                                                              |
| To evaluate the emergence of viral resistance to RDV                                                                                                                                                                                                                       | Emergence of viral resistance to RDV                                                                                                                                                                                              |
| To evaluate the safety, efficacy, and PK of RDV in participants with laboratory-confirmed COVID-19 with body mass index (BMI) for age ≥ 95t percentile as defined by the Centers for Disease Control and Prevention: https://www.cdc.gov/healthyweight/bmi/calculator.html | Safety, efficacy, and PK of RDV in overweight participants from Cohort 8 of age < 12 years and weight ≥ 40 kg                                                                                                                     |

The CHMP acknowledged that the final study report for GS-US-540-5823 was submitted with this variation application, which focuses on data from the paediatric patient population of cohorts 5, 6 and 7. The study design was assessed during evaluation of the initial submission.

<div style=\"page-break-after: always\"></div>

## Statistical methods

This submission focuses on data from Cohorts 5 to 7 in Study GS-US-540-5823 that support an expansion of  Veklury's  indication  to  include  the  treatment  of  COVID-19  in  neonates  less  than  28  days  of  age weighing at least 1.5 kg and preterm neonates and infants less than 56 days of age weighing at least 1.5 kg, as well as infants at least 28 days of age weighing between 1.5 kg to less than 3 kg.

To incorporate data from paediatric subjects enrolled in Study GS-US-540-5823 in previously developed population pharmacokinetic (PopPK) models of remdesivir (RDV) and its metabolites developed with data from studies GS-US-399-1812, GS-US-399-1954, GS-US-399-5505, GS-US-540-5823, GS-US-40-9012, and CO-US-540-5844 (REMDACTA), an updated population pharmacokinetic analysis was done.

Analysis of clinical efficacy endpoints was completed with the full analysis set.

The efficacy endpoints for Study GS-US-540-5823 include:

- Clinical improvement based on scoring using a 7-point ordinal scale (where 1 = death and 7 = not      hospitalized)
- Time (days) to discharge from hospital
- Days to the first confirmed negative polymerase chain reaction (PCR) result, where confirmed is defined as 2 consecutive negative PCR results
- Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first confirmed negative PCR result (whichever comes first)
- Oxygen usage and ventilation modality and settings

Clinical improvement based on scoring using the Paediatric Early Warning Score (PEWS) Scale

## Results

## Participant flow, Recruitment

The study was conducted at study centres in Italy, Spain, the United Kingdom, and the United States. Six participants were screened; 4 participants were enrolled in Cohort 5, 1 participant in Cohort 6, and 1 participant in Cohort 7. One participant in Cohort 5 enrolled but did not receive treatment due to withdrawal of consent by the parents.

## Conduct of the study

```
Table 7 lists the key dates relevant to the conduct of study GS-US-540-5823: Table 6 Study GS-US-540-5823: Key Dates 21 July 2020 (first participant screened)
```

```
Study Start Date: Study End Date: endpoint) 01 June 2023 (planned last participant last visit for this report)
```

<div style=\"page-break-after: always\"></div>

## Baseline data

The majority of participants in Cohorts 5 to 7 were female (60.0%; 3/5 participants) and White (80.0%; 4/5 participants).

The median (first quartile [Q1], third quartile [Q3]) age in Cohort 5 was 0.5 (0.5, 0.5) months (16 [15, 16] days), the participant in Cohort 6 was 0.4 months (12 days), and the participant in Cohort 7 was 1.0 month (30 days). The gestational age was ≥ 37 weeks for all participants in Cohort 5, 37 weeks for the participant in Cohort 6, and 32 weeks for the participant in Cohort 7. The median (Q1, Q3) baseline weight in Cohort 5 was 3.5 (2.8, 3.5) kg, the participant in Cohort 6 was 3.5 kg, and the participant in Cohort 7 was 2.2 kg.

<div style=\"page-break-after: always\"></div>

Table 7 GS-US-540-5823: Demographic and Baseline Characteristics (Safety Analysis Set)

|                        | Cohort 5: 14 to ≤ 28 Days, Gest.Age > 37 Weeks, and Weight2 25 kg (N=3)   | Cohort 6: <14 Days, Gest.Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: c 56 Days, Gest.Age ≤37 Weeks, and Birth Weight≥ 1.5 kg (N=1)   |
|------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Age (days)             |                                                                           |                                                                           |                                                                           |
| N                      | 3                                                                         | 1                                                                         | 1                                                                         |
| Mean (SD)              | 15.7 (0.58)                                                               | 12                                                                        | 30                                                                        |
| Median                 | 16                                                                        | 12                                                                        | 30                                                                        |
| Q1,Q3                  | 15, 16                                                                    | 12, 12                                                                    | 30, 30                                                                    |
| Min, max               | 15, 16                                                                    | 12, 12                                                                    | 30, 30                                                                    |
| Sex at birh            |                                                                           |                                                                           |                                                                           |
| Male                   | 2 (66.7%6)                                                                | 0                                                                         |                                                                           |
| Female                 | 1(33.3%)                                                                  | 1 (100.0%)                                                                | 1 (100.0%)                                                                |
| Race                   |                                                                           |                                                                           |                                                                           |
| Black                  | 口                                                                         | 1 (100.0%)                                                                | 0                                                                         |
| White                  | 3 (100.096)                                                               | 0                                                                         | 1 (100.0%6)                                                               |
| Ethnicity              |                                                                           |                                                                           |                                                                           |
| Not Hispanic or Latino | 3 (100.0%6)                                                               | 1 (100.0%)                                                                | 1 (100.0%)                                                                |
| Baseline weight (kg)   |                                                                           |                                                                           |                                                                           |
| N                      | m                                                                         | 1                                                                         | 1                                                                         |
| Mean (SD)              | 3.3 (0.40)                                                                | 3.5                                                                       | 2.2                                                                       |
| Median.                | 3.5                                                                       | 3.5                                                                       | 2.2                                                                       |
| Q1,Q3                  | 2.8, 3.5                                                                  | 3.5,3.5                                                                   | 2.2,2.2                                                                   |
| Min, max               | 2.8,3.5                                                                   | 3.5,3.5                                                                   | 2.2, 2.2                                                                  |
| Baseline height (cm)   |                                                                           |                                                                           |                                                                           |
| N                      | m                                                                         |                                                                           |                                                                           |
| Mean (SD)              | 50.0 (1.73)                                                               | 52.0                                                                      | 46.0                                                                      |
| Median.                | 51.0                                                                      | 52.0                                                                      | 46.0                                                                      |
| Q1, Q3                 | 48.0, 51.0                                                                | 52.0, 52.0                                                                | 46.0, 46.0                                                                |
| Min, max               | 48.0, 51.0                                                                | 52.0, 52.0                                                                | 46.0, 46.0                                                                |
| Baseline BMI (kg/m²)   |                                                                           |                                                                           |                                                                           |
| N                      | m                                                                         | 1                                                                         | 1                                                                         |
| Mean (SD)              | 13.0 (0.76)                                                               | 12.9                                                                      | 10.4                                                                      |
| Mediam.                | 13.5                                                                      | 12.9                                                                      | 10.4                                                                      |
| Q1, Q3                 | 12.2, 13.5                                                                | 12.9, 12.9                                                                | 10.4, 10.4                                                                |
| Min, max               | 12.2, 13.5                                                                | 12.9, 12.9                                                                | 10.4, 10.4                                                                |

<div style=\"page-break-after: always\"></div>

|                                         | Cohort 5: 14 to ≤28 Days, Gest.Age >37 Weeks, and Weight≥2.5 kg (N=3)   | Cohort6: ≤14 Days, Gest.Age >37 Weeks,and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: c 56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|-----------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Baseline BM-for-age percentile category |                                                                         |                                                                         |                                                                             |
| 5th percentile                          | 0                                                                       | 0                                                                       | 1 (100.0%)                                                                  |
| 25th.to95th percenile                   | 3 (100.096)                                                             | 1 (100.096)                                                             | 0                                                                           |
| 2 95thpercentile                        | 0                                                                       | 0                                                                       | 0                                                                           |

BMI =body mass index; CSR = clinical shudy report; Gest. = gestational; max =maximum, min = minimum; Q1 = first quartile; Q3 = third quartile; SD = standard deviation; WHO =Word Healith Organization

BMI (kg/m²) = weight (kg)/height (cm²) x 10,000.

BMI percentile for children c 24 months old was computed using WHO SAS* package: Www.who.inttoolkits/child-growthstandards/sofiware

Soumce: GS-US-540-5823 Final CSR, Table 15.8.3.1 and Listing 16.2.3.1

The study with cohorts 5, 6 and 7 was conducted from July 2020 to June 2023 (LPLV). The CHMP acknowledged  that  a  total  of  6  patients  were  screened  and  5  were  enrolled  in  the  study.  Three participants  were  enrolled  in  cohort  5  and  one  each  in  cohorts  6  and  7.  As  agreed  in  the  PIP (P/0439/2023), this number represents the minimum planned number of participants per cohort.

## Numbers analysed

The analysis sets used for data evaluation are shown in the table below (cohorts 5, 6, and 7).

<div style=\"page-break-after: always\"></div>

Table 8 Number of Participants (Analysed)

| Analysis Set                | Cohort l: 12 to ≤18 Years and Weight2 40 kg   | Cohort 2: 28 Days to ≤18 Years and Weight 20 to x40 kg   | Cohort 3: 28 Days to <18 Years and Weight 12 to c20 kg   | Cohort 4: 28 Days to <18 Years and Weight 3 to c12 kg   |
|-----------------------------|-----------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------|
| All Emrolled Analysis Set   | 12                                            | 12                                                       | 12                                                       | 12                                                      |
| Full Analysis Set           | 12 (100.0%)                                   | 12 (100.0%)                                              | 12 (100.0%)                                              | 12 (100.0%)                                             |
| Safety Analysis Set         | 12 (100.0%)                                   | 12 (100.0%)                                              | 12 (100.0%)                                              | 12 (100.0%)                                             |
| RDV PK Analysis Set         | 12 (100.0%)                                   | 12 (100.0%)                                              | 11 (91.7%)                                               | 10 (83.3%)                                              |
| Metabolites PK Analysis Set | 12 (100.0%)                                   | 12 (100.0%)                                              | 11 (91.7%)                                               | 10 (83.3%)                                              |
| SBECD PK Analysis Set       | 12 (100.0%)                                   | 12 (100.0%)                                              | 11 (91.7%)                                               | 10 (83.3%)                                              |

| Analysis Set                | Cohort 5: 14 to s 28 Days, Gest. Age > 37 Weeks, and Weight 21.5 kg   | Cohort 6: <14 Days, Gest. Age >37 Weeks, and Birth Weight 22.5 kg   | Cohort 7: c 56 Days, Gest. Age ≤37 Weeks, and Birth Weight 21.5 kg   | Cohort 8:  12 Years and Weight 240 kg   | Total      |
|-----------------------------|-----------------------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------|------------|
| All Emrolled Analysis Set   | 4                                                                     | 1                                                                   | 1                                                                    | 5                                       | 59         |
| Full Analysis Set           | 3 (75.0%)                                                             | 1 (100.0%)                                                          | 1 (100.0%)                                                           | 5 (100.0%)                              | 58 (98.3%) |
| Safety Analysis Set         | 3 (75.0%)                                                             | 1 (100.0%)                                                          | 1 (100.0%)                                                           | 5 (100.0%)                              | 58 (98.3%) |
| RDV PK Analysis Set         | 3 (75.0%)                                                             | 1 (100.0%)                                                          | 1 (100.0%)                                                           | 5 (100.0%)                              | 55 (93.2%) |
| Metabolites PK Analysis Set | 3 (75.0%)                                                             | 1 (100.0%)                                                          | 1 (100.0%)                                                           | 5 (100.0%)                              | 55 (93.2%) |
| SBECD PK Analysis Set       | 3 (75.0%)                                                             | 1 (100.0%)                                                          | 1 (100.0%)                                                           | 5 (100.0%)                              | 55 (93.2%) |

Gest = gestational; PK = pharmacokinetic(s); RDV = remdesivir; SBECD = sulfobutylether β-cyclodextrin sodium

The Full Analysis Set includes all participants who (a) were enrolled into the study and (b) received at least 1 dose of study dnug.

The RDV PK Analysis Set includes all participants who were enrolled and received at least 1 dose of RDV, and for whom PK concentrations of RDV were available.

The Safety Analysis Set includes all participants who (a) were enmrolled into the study and (b) received at least 1 dose of study dnug.

The Metabolites PK Analysis Set includes all participants who were emrolled and received at least 1 dose of RDV, and for whom PK concentrations of metabolite(s) (analytes) were available.

The SBECD PK Analysis Set includes all participants who are emrolled and have received at least 1 dose of RDV and for whom PK concentrations of SBECD are available.

The denominator for percentage is the number of enrolled participants.

## Outcomes and estimation

Of the 6 participants screened: 4 participants enrolled in Cohort 5, 1 participant in Cohort 6, and 1 participant  in  Cohort  7.  One  participant  in  Cohort  5  enrolled  but  did  not  receive  treatment  due  to withdrawal of consent by the parents. Thus, a total of five participants were treated with RDV.

The median (Q1, Q3) duration of hospitalization prior to the first dose of RDV in Cohort 5 was 5 (1, 9) days,  the  participant  in  Cohort  6  was  hospitalized  for  1  day,  and  the  participant  in  Cohort  7  was hospitalized for 3 days. The median (Q1, Q3) duration of symptoms prior to the first dose of RDV in Cohort 5 was 6 (2, 9) days, the participant in Cohort 6 had symptoms for 2 days, and the participant in Cohort 7 had symptoms for 9 days. At baseline, the only COVID-19-related disease manifestations observed in more than 1 participant were respiratory (4/5 participants). Three of 5 participants were on invasive mechanical ventilation (IMV), and 2 of 5 participants were on high-flow oxygen.

<div style=\"page-break-after: always\"></div>

Baseline SARS-CoV-2 RNA viral load from nasal/oropharyngeal (OP) swabs and endotracheal tube (ET) aspirates  was  measured  for  1  participant  each  in  Cohort  5;  5.02  log10  copies/mL  and  4.63  log10 copies/mL, respectively. The mean (SD) SARS-CoV-2 RNA viral load from nasopharyngeal (NP)/OP swabs was 5.99 (0.183) log10 copies/mL in Cohort 5 (2/3 participants), 4.11 log10 copies/mL for the participant in Cohort 6, and 8.53 log10 copies/mL for the participant in Cohort 7. The mean (SD) SARS-CoV-2 RNA viral load from rectal/faecal swabs was 4.27 (1.107) log10 copies/mL in Cohort 5 (3/3 participants), and 4.62 log10 copies/mL for the participant in Cohort 7. There was no baseline rectal/faecal swab sample for the participant in Cohort 6.

At baseline, median (Q1, Q3) alanine aminotransferase in Cohort 5 was 20 (15, 42) U/L, 8 U/L for the participant  in  Cohort  6,  and  9  U/L  for  the  participant  in  Cohort  7.  The  median  (Q1,  Q3)  aspartate aminotransferase in Cohort 5 was 69 (36, 73) U/L, 23 U/L for the participant in Cohort 6, and 23 U/L for the participant in Cohort 7. The median (Q1, Q3) creatinine in Cohort 5 was 0.4 (0.3, 0.5) mg/dL, 0.3 mg/dL for the participant in Cohort 6, and 0.3 mg/dL for the participant in Cohort 7.

<div style=\"page-break-after: always\"></div>

Table 9 GS-US-540-5823: Baseline Disease Characteristics (Safety Analysis Set)

|                                                               | Cohort 5: 14 to < 28 Days, Gest. Age > 37 Weeks, and Weight ≥2.5 kg (N=3)   | Cohort 6: < 14 Days, Gest. Age > 37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|---------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Duration of hospitalization prior to first dose of RDV (days) |                                                                             |                                                                              |                                                                            |
| N                                                             | 3                                                                           | 1                                                                            | 1                                                                          |
| Mean (SD)                                                     | 5 (4.0)                                                                     | 1                                                                            | 3                                                                          |
| Median                                                        | 5                                                                           | 1                                                                            | 3                                                                          |
| Q1, Q3                                                        | 1, 9                                                                        | 1, 1                                                                         | 3.3                                                                        |
| Min, max                                                      | 1,9                                                                         | 1,1                                                                          | 3.3                                                                        |
| Duration of symptoms prior to first dose of RDV (days)        |                                                                             |                                                                              |                                                                            |
| N                                                             | 3                                                                           | 1                                                                            | 1                                                                          |
| Mean (SD)                                                     | 6 (3.5)                                                                     | 2                                                                            | 9                                                                          |
| Median                                                        | 6                                                                           | 2                                                                            | 9                                                                          |
| Q1, Q3                                                        | 2.9                                                                         | 2,2                                                                          | 9.9                                                                        |
| Min, max                                                      | 2,9                                                                         | 2,2                                                                          | 9.9                                                                        |
| ALT (U/L)                                                     |                                                                             |                                                                              |                                                                            |
| N                                                             | 3                                                                           | 1                                                                            | 1                                                                          |
| Mean (SD)                                                     | 26 (14.4)                                                                   | 8                                                                            | 9                                                                          |
| Median                                                        | 20                                                                          | 8                                                                            | 9                                                                          |
| Q1, Q3                                                        | 15, 42                                                                      | 8,8                                                                          | 9.9                                                                        |
| Min, max                                                      | 15, 42                                                                      | 8.8                                                                          | 9.9                                                                        |
| AST (U/L)                                                     |                                                                             |                                                                              |                                                                            |
| N                                                             | 3                                                                           | 1                                                                            | 1                                                                          |
| Mean (SD)                                                     | 59 (20.3)                                                                   | 23                                                                           | 23                                                                         |
| Median                                                        | 69                                                                          | 23                                                                           | 23                                                                         |
| Q1, Q3                                                        | 36, 73                                                                      | 23,23                                                                        | 23, 23                                                                     |
| Min, max                                                      | 36, 73                                                                      | 23, 23                                                                       | 23, 23                                                                     |
| Oxygen support status                                         |                                                                             |                                                                              |                                                                            |
| Invasive mechanical ventilation                               | 2 (66.7%)                                                                   | 0                                                                            | 1 (100.0%)                                                                 |
| High-flow oxygen                                              | 1 (33.3%)                                                                   | 1 (100.0%)                                                                   | 0                                                                          |
| Low-flow oxygen                                               | 0                                                                           | 0                                                                            | 0                                                                          |
| Room air                                                      | 0                                                                           | 0                                                                            | 0                                                                          |
| COVID-19-related disease manifestations                       |                                                                             |                                                                              |                                                                            |
| Circulatory                                                   | 0                                                                           | 1 (100.0%)                                                                   | 0                                                                          |
| Gastrointestinal                                              | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |
| Neurological                                                  | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |
| Respiratory                                                   | 2 (66.7%)                                                                   | 1 (100.0%)                                                                   | 1 (100.0%)                                                                 |

<div style=\"page-break-after: always\"></div>

|                                                                          | Cohort 5: 14 to < 28 Days, Gest. Age >37 Weeks,and Weight≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age >37 Weeks,and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks,and Birth Weight ≥ 1.5 kg (N=1)   |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Systemic inflammatory response                                           | 0                                                                         | 0                                                                         | 1 (100.0%)                                                                |
| SARS-CoV-2RNAviral1oad (log1o copies) from nasal/OP swabsa               |                                                                           |                                                                           |                                                                           |
| N                                                                        | 1                                                                         | 0                                                                         | 0                                                                         |
| Mean (SD)                                                                | 5.02                                                                      | 一                                                                         | 一                                                                         |
| Median                                                                   | 5.02                                                                      | 一                                                                         | 一                                                                         |
| Q1, Q3                                                                   | 5.02, 5.02                                                                |                                                                           |                                                                           |
| Min, max                                                                 | 5.02, 5.02                                                                |                                                                           | 一                                                                         |
| SARS-CoV-2 RNAviral1oad (log1o copies) from NP/OP swabsa                 |                                                                           |                                                                           |                                                                           |
| N                                                                        | 2                                                                         | 1                                                                         | 1                                                                         |
| Mean (SD)                                                                | 5.99 (0.183)                                                              | 4.11                                                                      | 8.53                                                                      |
| Median                                                                   | 5.99                                                                      | 4.11                                                                      | 8.53                                                                      |
| Q1, Q3                                                                   | 5.86, 6.12                                                                | 4.11, 4.11                                                                | 8.53,8.53                                                                 |
| Min, max                                                                 | 5.86, 6.12                                                                | 4.11, 4.11                                                                | 8.53,8.53                                                                 |
| SARS-CoV-2 RNAviral1oad (log1o copies) from endotracheal tube aspiratesd |                                                                           |                                                                           |                                                                           |
| N                                                                        | 1                                                                         | 0                                                                         | 0                                                                         |
| Mean (SD)                                                                | 4.63                                                                      | 一                                                                         | 一                                                                         |
| Median                                                                   | 4.63                                                                      |                                                                           | 一                                                                         |
| Q1, Q3                                                                   | 4.63, 4.63                                                                | 一                                                                         | 一                                                                         |
| Min, max                                                                 | 4.63, 4.63                                                                | 一                                                                         | 一                                                                         |
| SARS-CoV-2 RNA viral1oad (log1o copies) from rectal/fecal swabsa         |                                                                           |                                                                           |                                                                           |
| N                                                                        | 3                                                                         | 0                                                                         | 1                                                                         |
| Mean (SD)                                                                | 4.27 (1.107)                                                              |                                                                           | 4.62                                                                      |
| Median                                                                   | 4.22                                                                      | 一                                                                         | 4.62                                                                      |
| Q1, Q3                                                                   | 3.19, 5.40                                                                | 一                                                                         | 4.62,4.62                                                                 |
| Min, max                                                                 | 3.19, 5.40                                                                | 一                                                                         | 4.62,4.62                                                                 |
| ECG interpretation                                                       |                                                                           |                                                                           |                                                                           |
| Normal                                                                   | 3 (100.0%)                                                                | 0                                                                         | 1 (100.0%)                                                                |
| Abnomal                                                                  | 0                                                                         | 1 (100.0%)                                                                | 0                                                                         |
| Clinically significant                                                   | 0                                                                         | 0                                                                         | 0                                                                         |
| Not clinically significant                                               | 0                                                                         | 1 (100.0%)                                                                | 0                                                                         |
| Missing/unknown                                                          | 0                                                                         | 0                                                                         | 0                                                                         |
| Creatinine (mg/dL)                                                       |                                                                           |                                                                           |                                                                           |
| N                                                                        | 3                                                                         | 1                                                                         | 1                                                                         |
| Mean (SD)                                                                | 0.4 (0.13)                                                                | 0.3                                                                       | 0.3                                                                       |
| Median                                                                   | 0.4                                                                       | 0.3                                                                       | 0.3                                                                       |

<div style=\"page-break-after: always\"></div>

|                                                                      | Cohort 5: 14to < 28 Days, Gest. Age >37 Weeks, and Weight ≥2.5 kg (N=3)   | Cohort 6: < 14 Days, Gest. Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|----------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Q1, Q3                                                               | 0.3, 0.5                                                                  | 0.3,0.3                                                                     | 0.3,0.3                                                                    |
| Min, max                                                             | 0.3, 0.5                                                                  | 0.3,0.3                                                                     | 0.3, 0.3                                                                   |
| eGFR using Bedside IDMS- traceable Schwartz fonmula (mL/min/1.73 m²) |                                                                           |                                                                             |                                                                            |
| N                                                                    | 0                                                                         | 0                                                                           | 0                                                                          |
| Mean (SD)                                                            |                                                                           |                                                                             |                                                                            |
| Median                                                               |                                                                           |                                                                             | 一                                                                          |
| Q1, Q3                                                               |                                                                           |                                                                             | 一                                                                          |
| Min, max                                                             |                                                                           |                                                                             |                                                                            |

ALT = alanine aminotransferase, AST = aspartate aminotransferase; CSR = clinical study report; ECG = electrocardiogram; min = minimum; NP = nasopharyngeal; OP = oropharyngeal; Q1 = first quartile; Q3 = third quartile; RDV = remdesivir;

SD = standard deviation

- a Per mL of transport medium.

Baseline was the last available value recorded on or prior to dosing.

A participant may have fit more than 1 COVID-19-related disease manifestation; therefore, percentages may add to more than 100%.

eGFR was calculated using Bedside IDMS-traceable Schwartz formula (mL/min/1.73 m²) for children aged 1 to &lt; 18 years. Source: GS-US-540-5823 Final CSR, Table 15.8.3.2

The CHMP acknowledged that a total of five participants were treated with RDV, three in cohort 5 and one each in cohorts 6 and 7. The median length of hospital stay prior to the first dose of RDV was 5 days in cohort 5 and 1 and 3 days in cohorts 6 and 7, respectively. Baseline SARS-CoV-2 RNA viral load was measured for all five participants using different sampling techniques, including nasopharyngeal/oropharyngeal, nasal/oropharyngeal and rectal/faecal swabs. The disease manifestations associated with COVID-19 were reported as respiratory in two of the five participants. Two other participants had a gastrointestinal or neurological manifestation. At baseline, three of the five participants were on invasive mechanical ventilation and two were on high flow oxygen support.

## Clinical Improvement Based on the 7-Point Ordinal Scale

All  5  participants  had  a  baseline  ordinal  scale  score  of  2  (hospitalized,  on  IMV  or  extracorporeal membrane oxygenation [ECMO]) or 3 (hospitalized,  on  noninvasive  ventilation  or  high-flow  oxygen devices). The baseline ordinal scale scores in Cohort 5 were 2 (66.7%; 2/3 participants) and 3 (33.3%; 1/3 participants). The participant in Cohort 6 had a score of 3, and the participant in Cohort 7 had a score of 2. By Day 10, the ordinal scale score for 1 participant in Cohort 5, with a baseline score of 3 (on high-flow oxygen), had increased to 7 (not hospitalized), and there was no change in ordinal scale score for any other participant in Cohort 5. At the time of the last assessment, the participant in Cohort 6 and the participant in Cohort 7 were also not hospitalized (ordinal scale scores of 7).

On Day 10, the median (Q1, Q3) changes from baseline in clinical status were as follows:

- Cohort 5: 0 (0.0, 4.0) points
- Cohort 6: 2.0 points
- Cohort 7: 2.0 points

At the time of the last assessment there was no change in clinical status from Day 10 for Cohort 5. The change from baseline at the time of the last assessment for the participant in Cohort 6 increased to 4.0 points, and for the participant in Cohort 7 increased to 5.0 points.

<div style=\"page-break-after: always\"></div>

Three participants (1 each in Cohorts 5 to 7) had a ≥ 2 -point improvement in clinical status on Day 10. There was no change in the proportion of participants who had a ≥ 2 -point improvement at the time of the last assessment. The times to a ≥ 2 -point improvement for these 3 participants with an ordinal scale score of ≤ 5 points at baseline were as follows:

- Cohort 5: 8 days
- Cohort 6: 10 days
- Cohort 7: 10 days

Three of the 5 participants (1 each in Cohorts 5 to 7) had a ≥ 1 -point improvement in clinical status on Day 10. There was no change in the proportion of participants who had a ≥ 1-point improvement at the time of the last assessment. The times to a ≥ 1 -point improvement for these 3 participants were as follows:

- Cohort 5: 8 days
- Cohort 6: 6 days
- Cohort 7: 6 days

In total, 1 of the 3 participants in Cohort 5 and neither of the participants in Cohorts 6 and 7 had recovered by Day 10 (Recovery, defined as an improvement from a baseline score of 2 through 5 to a score of 6 or 7 or an improvement from a baseline score of 6 to a score of 7). At the last assessment, the participants in Cohorts 6 and 7 had also fully recovered. In Cohort 5, there was no change in the proportion of participants who had recovered. Among the 3 participants who had recovered by the time of the last assessment, the times to recovery for each cohort were as follows:

- Cohort 5: 9 days
- Cohort 6: 13 days
- Cohort 7: 19 days

## Hospitalisation

In total, 3 participants (1 each in Cohorts 5 to 7) were discharged alive by Day 30. The remaining 2 participants in Cohort 5 were still hospitalised at Day 30. The durations of hospitalisation from Day 1 for the 3 participants who were discharged were as follows:

- Cohort 5: 9 days
- Cohort 6: 13 days
- Cohort 7: 19 days

The CHMP considered that, due to the single-arm design, the efficacy data presented are only descriptive and do not allow a firm conclusion on efficacy in the intended paediatric indication. In addition, the total number of five participants in cohorts 5, 6 and 7 is rather small and the interpretation of individual data points and the efficacy data in general should be considered with caution.

All participants had a baseline ordinal scale score of 2 or 3. Recovery was defined as an improvement from a baseline score of 2 through 5 to a score of 6 or 7 or an improvement from baseline score of 6 to a score of 7. For one participant in cohort 5, the score increased from 3 to 7. For all other participants in this cohort, no improvement was observed during the study. By Day 10, none of the participants in cohorts 6 or 7 had improved to a score of 6 or 7. However, both participants in cohort 6 or 7 improved to a score of 7 at the time of the final assessment. The time to recovery was 13 days for the participant

<div style=\"page-break-after: always\"></div>

in  cohort  6  and  19  days  for  the  participant  in  cohort  7.  The  two  participants  from  cohort  5  without improvement in the ordinal scale until the final assessment were still hospitalised at Day 30.

The efficacy outcome varied widely, from no improvement in the ordinal scale score for two participants to full recovery for the remaining three participants. It should be noted that the two participants in cohort 5  were  hospitalised  for  9  days/5  days  with  symptoms  present  for  9  days/6  days  prior  to  starting treatment with the first dose of RDV. The third participant in cohort 5 started RDV treatment earlier and was hospitalised for 1 day with symptoms present for 2 days. This participant made a full recovery compared to the other two cohort 5 participants. Participants in cohorts 6 and 7 were hospitalised for 1 and 3 days, with symptoms present for 2 and 9 days respectively. As the cohort 6 participant could be treated  with  high  flow  oxygen,  the  cohort  7  participant  required  IMV.  Both  participants  made  a  full recovery, taking 13 days for the participant in cohort 6 compared to 19 days for the participant in cohort 7.

## SARS-CoV-2 Viral Load

Confirmed negative SARS-CoV-2 PCR results (defined as 2 consecutive negative results or a negative result at the last available sample for participants who completed or discontinued from the study) on Day  2  through  Day  10  were  assessed  by  nasal/OP  samples,  NP/OP  samples,  ET  aspirates,  and rectal/faecal swabs. However, it should be noted that not all planned samples were collected.

Of the participants with a given type of sample collected, the proportion of participants with confirmed negative SARS-CoV-2 PCR results on Day 2 through Day 10 were reported as follows for each sample type:

- Nasal/OP samples:
- -Cohort 5 (1/1 participant): 100%
- NP/OP samples:
- -Cohort 5 (0/2 participants): 0%
- -Cohort 6 (0/1 participant): 0%
- -Cohort 7 (0/1 participant): 0%
- ET aspirates:
- -Cohort 5 (0/2 participants): 0%
- Rectal/fecal swabs:
- -Cohort 5 to 7: (5/5 participants): 100%

-

The median (Q1, Q3) times to negative SARS-CoV-2 PCR test result were as follows:

- Nasal/OP samples:
- -Cohort 5 (1/1 participant): 10 days
- Rectal/fecal swabs:
- -Cohort 5 (3/3 participants): 3 days (3, 5)
- -Cohort 6 (1/1 participant): 3 days
- -Cohort 7 (1/1 participant): 10 days

The SARS-CoV-2 RNA viral load (log10 copies/mL) from nasal/OP, NP/OP, ET aspirates, and rectal/fecal swabs at baseline, change at Day 10, and change at discharge through the first negative PCR result with confirmation are presented in Table 10.

Similar results were reported for the mean (SD) change from baseline in SARS-CoV-2 viral load up to Day 10, and change at discharge without the first negative PCR result with confirmation.

<div style=\"page-break-after: always\"></div>

Table 10 GS-US-540-5823: SARS-CoV-2 RNA Viral Load (Log10 Copies per mL) and Change From Baseline up to Day 10 or First Negative PCR Result With Confirmation (Full Analysis Set)

|                                      | Cohort 5: 14 to <28 Days, Gest. Age >37 Weeks, and Weight≥ 2.5 kg (N =3)   | Cohort 6: <14 Days, Gest. Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: < 56 Days, Gest. Age ≤37Weeks,and Birth Weight ≥ 1.5 kg (N=1)   |
|--------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Nasal/Oropharyngeal Samples          |                                                                            |                                                                            |                                                                           |
| Baseline/Day 1                       |                                                                            |                                                                            |                                                                           |
| N                                    | 1                                                                          | 0                                                                          | 0                                                                         |
| Mean (SD)                            | 5.02                                                                       | 一                                                                          |                                                                           |
| Median                               | 5.02                                                                       | 一                                                                          | 一                                                                         |
| Q1, Q3                               | 5.02, 5.02                                                                 |                                                                            |                                                                           |
| Min, max                             | 5.02, 5.02                                                                 |                                                                            | 一                                                                         |
| Change at Day 10                     |                                                                            |                                                                            |                                                                           |
| N                                    | 1                                                                          | 0                                                                          | 0                                                                         |
| Mean (SD)                            | -2.36                                                                      |                                                                            |                                                                           |
| Median                               | -2.36                                                                      | 一                                                                          | 一                                                                         |
| Q1, Q3                               | -2.36,-2.36                                                                | 一                                                                          | 一                                                                         |
| Min, max                             | -2.36,-2.36                                                                |                                                                            |                                                                           |
| Change at Day of Discharge           |                                                                            |                                                                            |                                                                           |
| N                                    | 0                                                                          | 0                                                                          | 0                                                                         |
| Mean (SD)                            |                                                                            |                                                                            |                                                                           |
| Median                               | 一                                                                          | 一                                                                          | 一                                                                         |
| Q1, Q3                               | 一                                                                          | 一                                                                          | 一                                                                         |
| Min, max                             |                                                                            | 一                                                                          |                                                                           |
| Nasopharyngeal/Oropharyngeal Samples |                                                                            |                                                                            |                                                                           |
| Baseline/Day 1                       |                                                                            |                                                                            |                                                                           |
| N                                    | 2                                                                          | 1                                                                          |                                                                           |
| Mean (SD)                            | 5.99 (0.183)                                                               | 4.11                                                                       | 8.53                                                                      |
| Median                               | 5.99                                                                       | 4.11                                                                       | 8.53                                                                      |
| Q1, Q3                               | 5.86, 6.12                                                                 | 4.11, 4.11                                                                 | 8.53, 8.53                                                                |
| Min, max                             | 5.86, 6.12                                                                 | 4.11, 4.11                                                                 | 8.53, 8.53                                                                |
| Change at Day 10                     |                                                                            |                                                                            |                                                                           |
| N                                    | 2                                                                          | 1                                                                          | 1                                                                         |

<div style=\"page-break-after: always\"></div>

|                             | Cohort 5: 14 to <28 Days, Gest. Age >37 Weeks, and Weight≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: < 56 Days, Gest. Age ≤37Weeks,and Birth Weight≥ 1.5 kg (N=1)   |
|-----------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Mean (SD)                   | -3.28 (0.183)                                                             | 0.28                                                                       | -4.26                                                                    |
| Median                      | -3.28                                                                     | 0.28                                                                       | -4.26                                                                    |
| Q1, Q3                      | -3.41, -3.15                                                              | 0.28,0.28                                                                  | -4.26,-4.26                                                              |
| Min, max                    | -3.41, -3.15                                                              | 0.28, 0.28                                                                 | -4.26, -4.26                                                             |
| Change at Day of Discharge  |                                                                           |                                                                            |                                                                          |
| N                           | 0                                                                         | 0                                                                          | 0                                                                        |
| Mean (SD)                   | 一                                                                         | 一                                                                          | 一                                                                        |
| Median                      | 一                                                                         | 一                                                                          | 一                                                                        |
| Q1, Q3                      | 一                                                                         | 一                                                                          | 一                                                                        |
| Min, max                    | 一                                                                         | 一                                                                          | 一                                                                        |
| Endotracheal Tube Aspirates |                                                                           |                                                                            |                                                                          |
| Baseline/Day 1              |                                                                           |                                                                            |                                                                          |
| N                           | 1                                                                         | 0                                                                          | 0                                                                        |
| Mean (SD)                   | 4.63                                                                      | 一                                                                          |                                                                          |
| Median                      | 4.63                                                                      |                                                                            |                                                                          |
| Q1, Q3                      | 4.63, 4.63                                                                |                                                                            | 一                                                                        |
| Min, max                    | 4.63, 4.63                                                                | 一                                                                          |                                                                          |
| Change at Day 10            |                                                                           |                                                                            |                                                                          |
| N                           | 1                                                                         | 0                                                                          | 0                                                                        |
| Mean (SD)                   | -1.92                                                                     | 一                                                                          | 一                                                                        |
| Median                      | -1.92                                                                     | 一                                                                          | 一                                                                        |
| Q1, Q3                      | -1.92,-1.92                                                               | 一                                                                          | 一                                                                        |
| Min, max                    | -1.92, -1.92                                                              | 一                                                                          | 一                                                                        |
| Change at Day of Discharge  |                                                                           |                                                                            |                                                                          |
| N                           | 0                                                                         | 0                                                                          | 0                                                                        |
| Mean (SD)                   | 一                                                                         | 一                                                                          | 一                                                                        |
| Median                      | 一                                                                         | 一                                                                          | 一                                                                        |
| Q1, Q3                      | 一                                                                         | 一                                                                          | 一                                                                        |
| Min, max                    |                                                                           |                                                                            |                                                                          |
| Rectal orFecal Swabs        |                                                                           |                                                                            |                                                                          |
| Baseline/Day 1              |                                                                           |                                                                            |                                                                          |
| N                           | 3                                                                         | 0                                                                          | 1                                                                        |

<div style=\"page-break-after: always\"></div>

|                            | Cohort 5: 14 to <28 Days, Gest. Age > 37 Weeks, and Weight≥ 2.5 kg (N=3)   | Cohort 6: < 14 Days, Gest. Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N =1)   | Cohort 7: < 56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|----------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Mean (SD)                  | 4.27 (1.107)                                                               |                                                                              | 4.62                                                                        |
| Median                     | 4.22                                                                       |                                                                              | 4.62                                                                        |
| Q1, Q3                     | 3.19, 5.40                                                                 |                                                                              | 4.62,4.62                                                                   |
| Min, max                   | 3.19, 5.40                                                                 |                                                                              | 4.62,4.62                                                                   |
| Change at Day 10           |                                                                            |                                                                              |                                                                             |
| N                          | 0                                                                          | 0                                                                            | 1                                                                           |
| Mean (SD)                  |                                                                            |                                                                              | -2.43                                                                       |
| Median                     |                                                                            |                                                                              | -2.43                                                                       |
| Q1, Q3                     |                                                                            |                                                                              | -2.43,-2.43                                                                 |
| Min, max                   |                                                                            |                                                                              | -2.43,-2.43                                                                 |
| Change at Day of Discharge |                                                                            |                                                                              |                                                                             |
| N                          | 0                                                                          | 0                                                                            | 0                                                                           |
| Mean (SD)                  |                                                                            |                                                                              |                                                                             |
| Median                     |                                                                            |                                                                              |                                                                             |
| Q1, Q3                     |                                                                            |                                                                              |                                                                             |
| Min, max                   |                                                                            |                                                                              |                                                                             |

CSR = clinical study report; Gest. = gestational; LOD = limit of detection; LLOQ = 1ower limit of quantitation; max = maximum; deviation

Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first).

Baseline was the last available value recorded on or prior to dosing.

copies/mL. Records with \"&lt; 1018cp/mL SARSCoV2 detected\" were imputed as 509 copies/mL; \"No SARS-CoV-2 detected\" were imputed as 462.5 copies/mL.

For rectal/fecal swabs: LLOQ = 488 copies/mL; LOD = 306 copies/mL. Records with \"&lt; 488cp/mL SARSCoV2 detected\" were imputed as 244 copies/mL; \"No SARS-CoV-2 detected were imputed as 153 copies/mL.

Viral load data after participants taking chloroquine, hydroxychloroquine, bamlanivimab, casirivimab/imdevimab, molnupiravir, lopinavif-ritonavif, and ribavirin during the study were excluded from the summaries.

Source: GS-US-540-5823 Fimal CSR, Table 15.9.4.1.1, Table 15.9.4.2.1, Table 15.9.4.3.1, and Table 15.9.4.4.1

The CHMP noted that the reduction in viral load for study participants was shown by SARS-CoV-2 PCR results from Day 2 to Day 10. As noted by the MAH, not all planned samples were collected. According to the study protocol, nasal and oropharyngeal samples (combined, if unable to collect nasopharyngeal and oropharyngeal sample) and rectal or faecal swabs should have been collected on days 3, 5, 7 and 10 or at discharge if earlier. Endotracheal tube aspirates should have been collected on the same days in case the participant was intubated. It is not clear from the information provided why not all planned procedures were carried out and why the swab collection technique for SARS-CoV-2 RT-qPCR testing was not consistent on Day 1, 3, 5, 7 and 10. The comparability of viral load results between and within cohorts may have been greatly affected by the different sampling techniques used. However, the PCR data showed a clear reduction in viral load. As only a single arm was tested, it is difficult to interpret the efficacy of RDV on viral load reduction.

<div style=\"page-break-after: always\"></div>

## Oxygen Usage and Ventilation Modality

In  Cohort 5, 1 of the 3 participants was on high-flow oxygen from baseline to Day 7. Following an improvement in their condition, this participant was switched to room air on Day 8, prior to discharge from hospital on Day 9. The other 2 participants in Cohort 5 were on IMV from baseline until the last available assessment and were still hospitalized at Day 30.

The participant in Cohort 6 was on high-flow oxygen from baseline to Day 5. As the participant's condition improved, they were switched to low-flow oxygen from Day 6 to Day 9 and then to room air on Day 10. The participant was discharged from hospital on Day 13.

The participant in Cohort 7 was on IMV from baseline to Day 5. As the participant's condition improved, they were switched to high-flow oxygen from Day 6 to Day 9 and then to low-flow oxygen on Day 10. The participant was discharged from hospital on Day 19.

The CHMP noted that two of the five participants remained on invasive mechanical ventilation (IMV) without any improvement until the final assessment on Day 30, both from cohort 5. A third participant (cohort  7)  started  the  study  on  IMV  and  was  able  to  switch  to  low-flow  oxygen  on  Day  10.  Two participants, one from cohort 5 and one from cohort 6, started on high-flow oxygen and improved enough to be taken off supplemental oxygen on Days 8 and 10, respectively.

For both participants in cohort 5 without improvement, additionally, the ordinal scale score did not show recovery as defined in the study protocol.

## PEWS Scale

Clinical scoring using the PEWS Improvement Scale was performed at screening and daily for the duration of  RDV  dosing  in  Study  GS-US-540-5823.  The  PEWS  scale  is  comprised  of  3  subscales  (behaviour, cardiovascular, and respiratory) each with a score of 0 to 3 to give a total score of 0 to 9. An improvement in the participant's condition is measured as a reduction in PEWS score.

Behaviour:

The PEWS behaviour scores at baseline in Cohort 5 were 3 (66.7%; 2/3 participants), and 1 (33.3%; 1/3 participants). The participant in Cohort 6 had a score of 2 and the participant in Cohort 7 had a score of 3. By Day 10, 4 participants had improvements in PEWS behaviour score: 2 participants in Cohort 5 (with baseline scores of 3 and 1, respectively) had decreases of 1 point, the participant in Cohort 6 had a decrease of 2 points, and the participant in Cohort 7 had a decrease of 2 points. The same results were observed at the time of last assessment.

Cardiovascular:

The PEWS cardiovascular scores at baseline in Cohort 5 were 1 (66.7%; 2/3 participants), and 0 (33.3%; 1/3 participants). The participant in Cohort 6 had a score of 2, and the participant in Cohort 7 had a score of 0. By Day 10, 2 participants had improvements in PEWS cardiovascular score: 1 participant in Cohort 5 had a decrease of 1 point, and the participant in Cohort 6 had a decrease of 2 points. The same results were observed at the time of last assessment.

Respiratory:

The PEWS respiratory scores at baseline in Cohort 5 were 1 (33.3%; 1/3 participants), and 3 (66.7%; 2/3 participants). The participant in Cohort 6 had a baseline score of 2, and the participant in Cohort 7 had a baseline score of 3. By Day 10, 3 participants had improvements in PEWS respiratory score: the participant in Cohort 5 with a baseline score of 1 decreased by 1 point, the participant in Cohort 6 had

<div style=\"page-break-after: always\"></div>

a decrease of 2 points, and the participant in Cohort 7 had a decrease of 3 points. The same results were observed at the time of last assessment.

Total Score:

The PEWS total scores (maximum score of 9) at baseline in Cohort 5 were 2 (33.3%; 1/3 participants) and 7 (66.7%; 2/3 participants). The participant in Cohort 6 had a baseline score of 6, and the participant in Cohort 7 had a baseline score of 6. By Day 10, all 5 participants had improvements in PEWS total score: in Cohort 5 there was a 2-point decrease in 1 participant, and a 1-point decrease in 2 participants. The participant in Cohort 6 had a decrease of 6 points, and the participant in Cohort 7 had a decrease of 5 points. The same results were observed at the time of last assessment.

Table 11. GS-US-540-5823: Change From Baseline in PEWS Score-Total Score (Full Analysis Set)

|                                                  | Cohort 5: 14 to < 28 Days, Gest. Age > 37 Weeks, and Weight≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age > 37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|--------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Change frombaseline on Day 10                    |                                                                             |                                                                             |                                                                             |
| N                                                | 3                                                                           | 1                                                                           | 1                                                                           |
| Mean (SD)                                        | -1.3 (0.58)                                                                 | -6.0                                                                        | -5.0                                                                        |
| Median                                           | -1.0                                                                        | -6.0                                                                        | -5.0                                                                        |
| Q1, Q3                                           | -2.0,-1.0                                                                   | -6.0,-6.0                                                                   | -5.0,-5.0                                                                   |
| Min, max                                         | -2, -1                                                                      | -6, -6                                                                      | -5, -5                                                                      |
| Change from baseline onlast available assessment |                                                                             |                                                                             |                                                                             |
| N                                                | 3                                                                           | 1                                                                           | 1                                                                           |
| Mean (SD)                                        | -1.3 (0.58)                                                                 | -6.0                                                                        | -5.0                                                                        |
| Median                                           | -1.0                                                                        | -6.0                                                                        | -5.0                                                                        |
| Q1, Q3                                           | -2.0,-1.0                                                                   | -6.0,-6.0                                                                   | -5.0,-5.0                                                                   |
| Min, max                                         | -2,-1                                                                       | -6,-6                                                                       | -5,-5                                                                       |

CSR = clinical study report; Gest. = gestational; max = maximum; min = minimum; PEWS = Pediatric Early Waming Score; Q1 = first quartile; Q3 = third quartile; RDV = remdesivir, SD = standard deviation

Baseline was the last available value recorded on or prior to dosing for RDV. A negative change from baseline value indicates an improvement.

Source: GS-US-540-5823 Final CSR, Table 15.9.2.2.4

Total score was the sum of behavior, cardiovascular, and respiratory.

The CHMP noted that all participants improved their PEWS score by at least one point by Day 10. In particular,  the  two  participants  from  cohorts  6  and  7  improved  significantly  by  6  and  5  points respectively. For the two cohort 5 participants who remained in ordinal score 2 for the whole study, the PEWS score improved by one point.

## SARS-CoV-2 variants

At baseline, the amino acid substitutions nsp12 P227L, nsp12 P323L, and nsp13 P77L were observed in the SARS-CoV-2 RNA from participants in Cohorts 5 to 7. The EC50 fold changes of nsp12 P227L and

<div style=\"page-break-after: always\"></div>

nsp13 P77L were 1.11- and 0.53-fold, respectively, indicating similar susceptibility to RDV as the wildtype reference sequence.

At postbaseline, 1 of 4 participants with sequencing data at both baseline and postbaseline available had emergent substitutions in nsp12. The nsp12 V166V/L amino acid substitution emerged at Day 10 as a mixture with wild type in 1 participant who was treated with RDV for 5 days. This participant experienced an ordinal scale ≥ 2 -point improvement at Day 10 and was released from the hospital on Day 13. The EC50 fold change was 1.85 for the nsp12 V166L substitution using the subgenomic replicon system, indicating similar susceptibility to RDV as the wild-type reference sequence.

The CHMP noted that, in one participant, an emergent substitution was identified postbaseline. The nsp12 V166V/L amino acid substitution was shown to have a similar susceptibility to RDV as the wild-type reference sequence.

## 2.4.2. Discussion on clinical efficacy

Study GS-US-540-5823 is a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir (GS-5734™) in participants from birth to &lt; 18 years of age with COVID-19. In cohorts 5 to 7, clinical efficacy  was only assessed in participants who  were hospitalised. This should be noted as the proposed indication extension includes paediatric patients (1.5 kg to &lt;40 kg body weight) who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 and are thus typically not hospitalised. The study was planned with 22 study centres in Italy, Spain, the United Kingdom, and the United States. Cohorts 5 to 7 from Study GSUS-540-5823 are included in this submission. The primary objectives were to evaluate the safety and tolerability of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to &lt; 18 years and to evaluate the PK of RDV in participants with laboratory-confirmed COVID-19 aged 0 days to &lt; 18 years. The additional secondary endpoints are related to efficacy and safety (Table 6).

In this study, dose selection of RDV to be evaluated in paediatric participants targeted similar exposures to those observed in adults. Dose selection for participants in Cohort 5 was informed by a physiologically based  pharmacokinetic  (PBPK)  model  developed  to  characterize  the  PK  of  RDV  and  the  primary circulating nucleoside metabolite, GS-441524, in adults (SimCYP Version 17, Certara). For dose selection in Cohorts 6 and 7, a population pharmacokinetic (PopPK) model was used (with data from Cohorts 1 to 4 and Cohort 8 and 1 participant in Cohort 5) to predict paediatric patient exposures.

Of the 6 participants screened; 4 participants enrolled in Cohort 5, 1 participant in Cohort 6, and 1 participant  in  Cohort  7.  One  participant  in  Cohort  5  enrolled  but  did  not  receive  treatment  due  to withdrawal of consent by the parents.

The median (Q1, Q3) duration of hospitalization prior to the first dose of RDV in Cohort 5 was 5 (1, 9) days,  the  participant  in  Cohort  6  was  hospitalized  for  1  day,  and  the  participant  in  Cohort  7  was hospitalized for 3 days. The median (Q1, Q3) duration of symptoms prior to the first dose of RDV in Cohort 5 was 6 (2, 9) days, the participant in Cohort 6 had symptoms for 2 days, and the participant in Cohort 7 had symptoms for 9 days. At baseline, the only COVID-19-related disease manifestations observed in more than 1 participant were respiratory (4/5 participants). Three of 5 participants were on invasive mechanical ventilation (IMV), and 2 of 5 participants were on high-flow oxygen.

All participants had a baseline ordinal scale score of 2 or 3. Recovery was defined as an improvement from a baseline score of 2 through 5 to a score of 6 or 7 or an improvement from baseline score of 6 to a score of 7. For one participant in cohort 5, the score increased from 3 to 7. For all other participants in this cohort, no improvement was observed during the study. By Day 10, none of the participants in cohorts 6 or 7 had improved to a score of 6 or 7. However, both participants in cohort 6 or 7 improved

<div style=\"page-break-after: always\"></div>

to a score of 7 at the time of the final assessment. The time to recovery was 13 days for the participant in  cohort  6  and  19  days  for  the  participant  in  cohort  7.  The  two  participants  from  cohort  5  without improvement in the ordinal scale until the final assessment were still hospitalised at Day 30.

The reduction in viral load for study participants is shown by SARS-CoV-2 PCR results from day 2 to day 10. As noted by the MAH, not all planned samples were collected. It is not clear from the information provided why not all planned procedures were carried out and why the swab collection technique for SARS-CoV-2 RT-qPCR testing was not consistent on Day 1, 3, 5, 7 and 10. The comparability of viral load  results  between  and  within  cohorts  may  have  been  greatly  affected  by  the  different  sampling techniques used. However, the PCR data show a clear reduction in viral load.

Two of the five participants remained on invasive mechanical ventilation (IMV) without any improvement until the final assessment on Day 30, both from cohort 5. A third participant (cohort 7) started the study on IMV and was able to switch to low flow oxygen on Day 10. Two participants, one from cohort 5 and one from cohort 6, started on high flow oxygen and improved enough to be taken off supplemental oxygen on Days 8 and 10 respectively.

All  participants  improved  their  PEWS  score  by  at  least  one  point  by  day  10.  In  particular,  the  two participants from cohorts 6 and 7 improved significantly by 6 and 5 points respectively. For the two cohort 5 participants who remained in ordinal score 2 for the whole study, the PEWS score improved by one point.

Cohorts 5 to 7 did not collect data from paediatric participants who were not hospitalised. Comparison of the steady-state RDV AUCtau of hospitalised paediatric participants with non-hospitalised adult participants from the Phase 3 studies (Figure 1) shows an overall trend towards higher RDV levels in paediatric participants. Further elaboration of the effect of intrinsic factors such as baseline oxygen or hospitalisation status of paediatric participants did not show a statistically significant effect on the PK of RDV. Due to the limited number of paediatric participants in cohorts 5 to 7, the effect of hospitalisation was further assessed using virtual populations of paediatric study cohorts. This analysis showed no clinically significant difference in RDV Cmax and AUCtau (within the 5 th  and 95 th  percentile bounds of observed exposures in adults with COVID-19 in Phase 3 studies), suggesting no significant effect of hospitalisation status on efficacy (Table 2).

## Efficacy data and additional analyses

Using virtual populations of neonates and preterm neonates and infants, the overall range of PopPK model-simulated steady-state exposures (AUCtau and Cmax; Ctau for GS-445124 only) of RDV and its metabolites at the 2.5/1.25 mg/kg loading/maintenance dose were within the 5th and 95th percentiles of exposures in hospitalized adult participants with severe COVID-19 pneumonia on supplemental oxygen and  non-hospitalized  adult  participants  with  COVID-19  at  risk  for  disease  progression  and  not  on supplemental oxygen in the Phase 3 studies CO-US-540-5844 and GS-US-540-9012, respectively.

For a virtual population of infants weighing between 1.5 kg and less than 3 kg (not evaluated in Study GS-US-540-5823), the  overall  range  of  PopPK  model-simulated  steady-state  exposures  (AUCtau  and Cmax; Ctau for GS-445124 only) of RDV and its metabolites at the 2.5/1.25 mg/kg loading/maintenance dose were within the 5th and 95th percentiles of exposures in hospitalized adult participants with severe COVID-19 pneumonia on supplemental oxygen and non-hospitalized adult participants with COVID-19 at risk for disease progression and not on supplemental oxygen in the Phase 3 studies CO-US-540-5844 and GS-US-540-9012, respectively.

In summary, according to the MAH these data supported the proposed clinical dosing regimen of IV RDV in the paediatric populations described in Table 12.

<div style=\"page-break-after: always\"></div>

Table 12. Proposed RDV Dosage in Paediatric Patients Weighing at Least 1.5 kg

| Pediatric Patient Population                                                   | RDV Loading Dose   | RDV Maintenance Dose                                                             |
|--------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------------|
| Neonates less than 28 days of age weighing at least 1.5 kg                     | 2.5 mg/kg on Day 1 | 1.25 mg/kg once daily from Day 2 for a total treatment duration of up to 10 days |
| Preterm neonates and infants less than 56 days of age weighing at least 1.5 kg | 2.5 mg/kg on Day 1 | 1.25 mg/kg once daily from Day 2 for a total treatment duration of up to 10 days |
| Infants at least 28 days of age weighing between 1.5 kg to less than 3 kg      | 2.5 mg/kg on Day 1 | 1.25 mg/kg once daily from Day 2 for a total treatment duration of up to 10 days |

## RDV =remdesivir

The CHMP noted that the proposed dosing regimen was tested in a virtual population of neonates and preterm infants, and in a virtual population of infants weighing between 1.5 and less than 3 kg. The simulated steady-state parameters of RDV and its metabolites showed exposures within the 5th and 95th percentiles of known exposures in hospitalised adult patients with severe COVID-19 pneumonia on supplemental  oxygen  and  in  non-hospitalised  adult  patients  with  COVID-19  at  risk  of  disease progression.

In addition, the extrapolation of adult efficacy and safety data to paediatric patients is based on matching paediatric and adult systemic exposures.

With regard to the extension of the indication to paediatric patients weighing 1.5 kg to &lt;40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19, similarity  of  disease  as  an  assumption  allowing  extrapolation  from  adults  needed  to  be  presented following the 'Structured guidance on the use of extrapolation' published on the EMA website. The MAH was requested to:

- Review all relevant data to identify potential differences between characteristics of adults and paediatric patients (1.5 kg to &lt;40 kg) of different age groups;

- Exploit existing evidence in the extrapolation concept including the comparability of risk factors and the risk of progression to severe disease status in adults and paediatric patients (1.5 kg to &lt;40 kg) of different age groups;

- Discuss the applicability of risk factors for progression to severe COVID-19 as defined in GS-US-5409012.

The provided review of data from the MAH on the similarity of disease characteristics between paediatric and adult patients indicates that although there are physiological differences (e.g. organ maturation, liver and kidney function, body size), no significant discrepancies have been identified in the characteristics of adults and paediatric patients of different age groups with regard to disease progression and clinical outcome. The characteristics of the symptoms and their intensity can vary between paediatric and adult patients. Certain comorbidities are unique, or more common in, children, which increases their risk for severe COVID-19 (e.g. prematurity, genetic diseases, congenital heart disease). In general, the severity of the disease tends to be less in children; however, the general characteristics of the disease and many risk factors for severe COVID-19 are similar in children and adults.

It could therefore be concluded that there is sufficient similarity between the disease characteristics, risk factors and the risk of severe progression for both paediatric and adult patients. The risk factors for progression to severe disease as defined in PINETREE (GS-US-540-9012) are consistent with those identified in the literature for paediatric and adult patients.

<div style=\"page-break-after: always\"></div>

More data would however be needed to allow for dosing recommendations in the vulnerable neonate population.

## 2.4.3. Conclusions on the clinical efficacy

The efficacy data should be interpreted with caution as the study was conducted as a single arm study. The efficacy data are descriptive only. Viral load assessments show a reduction from baseline to day 10. However, the sampling technique was not consistent throughout the study and may have contributed to inconsistent results. The data on oxygen consumption and ventilation modality show that three of the five participants improved significantly and were off supplemental oxygen or on low flow oxygen by day 10. Two participants showed no improvement.

There is  sufficient  similarity  between  the  disease  characteristics,  risk  factors  and  the  risk  of  severe progression for paediatric and adult patients. The risk factors for progression to severe disease as defined in PINETREE (GS-US-540-9012) are consistent with those identified in the literature for paediatric and adult patients.

More data in the neonate population would however be needed to allow for dosing recommendations.

## 2.5. Clinical safety

## Introduction

In support of this application for extension of indications, the Applicant presented safety data from the following clinical study:

- Study GS-US-540-5823 : Safety data from the final analysis of the Phase 2/3 Study GS-US540-5823, including neonates less than 28 days of age and preterm neonates and infants less than 56 days of age in Cohorts 5 to 7, to include the treatment of COVID-19 in paediatric patients from birth weighing at least 1.5 kg.

Safety data from Cohorts 1 to 4 and Cohort 8 in Study GS-US-540-5823 were provided in previous submissions to support Veklury's current indication for the treatment of COVID-19.

## Patient exposure

Participants  were  to  receive  up  to  10  doses  of  study  drug;  participants  who  demonstrated  clinical improvement could be considered for a shorter treatment period of fewer than 10 days.

<div style=\"page-break-after: always\"></div>

Table 13. GS-US-540-5823: Exposure to Study Drug (Safety Analysis Set)

|                          | Cohort 5: 14 to < 28 Days, Gest. Age >37 Weeks, and Weight≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age >37 Weeks,and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N =1)   |
|--------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Number of doses received |                                                                            |                                                                           |                                                                             |
| N                        | 3                                                                          | 1                                                                         | 1                                                                           |
| Mean (SD)                | 9 (1.2)                                                                    | 5                                                                         | 10                                                                          |
| Median                   | 10                                                                         | 5                                                                         | 10                                                                          |
| Q1, Q3                   | 8,10                                                                       | 5.5                                                                       | 10,10                                                                       |
| Min, max                 | 8.10                                                                       | 5.5                                                                       | 10, 10                                                                      |
| Number of doses received |                                                                            |                                                                           |                                                                             |
| 5 doses                  | 0                                                                          | 1 (100.0%)                                                                | 0                                                                           |
| 8 doses                  | 1 (33.3%)                                                                  | 0                                                                         | 0                                                                           |
| 10 doses                 | 2 (66.7%)                                                                  | 0                                                                         | 1 (100.0%)                                                                  |

CSR = clinical study report; Gest. = gestational; max = maximum; min = minimum; Q1 = first quartile; Q3 = third quartile; SD = standard deviation

Source: GS-US-540-5823 Final CSR, Table 15.11.1.1

The CHMP noted that three of the five participants received the maximum of 10 planned doses of RDV. In cohorts 5 and 6, one participant was stopped after eight and five doses, respectively, due to clinical improvement.

## Adverse events

Common adverse events in patients treated with COVID-19 included nausea, headache and rash. In addition,  increases  in  alanine  aminotransferase  (ALT)  and  aspartate  aminotransferase  (AST)  and prolongation of prothrombin time or IRN were observed in clinical trials.

## Summary of Adverse Events:

There were 3 participants who had at least 1 AE: 2 participants in Cohort 5, and the participant in Cohort 6. No AEs were reported in more than 1 participant. One participant in Cohort 5 experienced 5 Grade 4 AEs, all of which were serious adverse events (SAEs). The participant in Cohort 6 also had an SAE. The severity of AEs was graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events, Version 2.1 dated July 2017.

There  were  no  AEs  considered  related  to  study  drug,  no  AEs  leading  to  premature  study  drug discontinuation, and no treatment-emergent deaths reported in Cohorts 5 to 7.

<div style=\"page-break-after: always\"></div>

Table 14. GS-US-540-5823: Overall Summary of Adverse Events (Safety Analysis Set)

|                                                    | Cohort 5: 14 to <28 Days, Gest. Age > 37 Weeks, and Weight ≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age > 37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   |   Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1) |
|----------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| AE                                                 | 2 (66.7%)                                                                   | 1 (100.0%)                                                                  |                                                                          0 |
| Grade 3 or higher AE                               | 1 (33.3%)                                                                   | 0                                                                           |                                                                          0 |
| Study drug-related AE                              | 0                                                                           | 0                                                                           |                                                                          0 |
| Study dnug-related Grade 3 or higher AE            | 0                                                                           | 0                                                                           |                                                                          0 |
| SAE                                                | 1 (33.3%)                                                                   | 1 (100.0%)                                                                  |                                                                          0 |
| Study dnug-related SAE                             | 0                                                                           | 0                                                                           |                                                                          0 |
| AE leading to premature study dnug discontinuation | 0                                                                           | 0                                                                           |                                                                          0 |
| Treatment-emergent death                           | 0                                                                           | 0                                                                           |                                                                          0 |

AE = adverse event; CSR = clinical study report; DAIDS = Division of AIDS; Gest. = gestational; MedDRA = Medical Dictionary for Regulatory Activities; SAE = serious adverse event

AEs were coded using MedDRA Version 26.0.

Severity grades were defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, July 2017.

Treatment-emergent death refers to deaths that occurred between the first dose date and the last dose date plus 30 days (inclusive).

Source: GS-US-540-5823 Final CSR, Table 15.11.2.1.1

Table 15 shows the adverse events recorded for cohorts 5 to 7 using MedDRA version 26.0.

<div style=\"page-break-after: always\"></div>

Table 15. GS-US-540-5823: Adverse Events Reported in Participants in Cohorts 5 to 7 (Safety Analysis Set)

|                                            | Cohort 5: 14 to < 28 Days, Gest. Age >37 Weeks, and Weight ≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age > 37 Weeks, and Birth Weight ≥2.5 kg (N=1)   |   Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight≥ 1.5 kg (N=1) |
|--------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Number of participants experiencing any AE | 2 (66.7%)                                                                   | 1 (100.0%)                                                                 |                                                                         0 |
| Acidosis                                   | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Anaemia                                    | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Bacterial disease carrier                  | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Cardiopulmonary failure                    | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Chest wall haematoma                       | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Conjunctivitis                             | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Hypertension                               | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Infusion-site extravasation                | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Pneumothorax                               | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Seizure                                    | 1 (33.3%)                                                                   | 0                                                                          |                                                                         0 |
| Urinary tract infection                    | 0                                                                           | 1 (100.0%)                                                                 |                                                                         0 |

AE = adverse event; CSR = clinical study report; Gest. = gestational; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term

AEs were coded using MedDRA Version 26.0.

PTs were presented by descending order of the total frequencies.

Multiple AEs were counted only once per participant per PT.

Treatment-emergent adverse events are (1) any AEs that begin on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days, or (2) any AEs leading to premature discontinuation of study dug. Source: GS-US-540-5823 Final CSR, Table 15.11.2.1.4

## Serious adverse events/deaths/other significant events

There was 1 participant in Cohort 5 with a medical history of respiratory failure who experienced 5 Grade 4 AEs during the study (cardiopulmonary failure [2 events], acidosis, pneumothorax, and seizure). All 5 events were SAEs. There were no Grade 3 AEs. Table 16summarises the SAEs recorded during the study.

There were no AEs considered related to study drug reported in Cohorts 5 to 7. There were no treatmentemergent deaths reported in Cohorts 5 to 7 during the study. There were no participants in Cohorts 5 to 7 who discontinued study drug prematurely due to an AE.

<div style=\"page-break-after: always\"></div>

Table 16. GS-US-540-5823: Serious Adverse Events (Safety Analysis Set)

|                                                   | Cohort 5: 14 to < 28 Days, Gest. Age > 37 Weeks, and Weight≥ 2.5 kg (N=3)   | Cohort 6: <14 Days, Gest. Age > 37 Weeks, and Birth Weight ≥ 2.5 kg (N=1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|---------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Number of participants experiencing any SAE       | 1 (33.3%)                                                                   | 1 (100.0%)                                                                  | 0                                                                          |
| Number of participants experiencing any SAE by PT | Number of participants experiencing any SAE by PT                           | Number of participants experiencing any SAE by PT                           | Number of participants experiencing any SAE by PT                          |
| Acidosis                                          | 1 (33.3%)                                                                   | 0                                                                           | 0                                                                          |
| Cardiopulmonary failure                           | 1 (33.3%)                                                                   | 0                                                                           | 0                                                                          |
| Pneumothorax                                      | 1 (33.3%)                                                                   | 0                                                                           | 0                                                                          |
| Seizure                                           | 1 (33.3%)                                                                   | 0                                                                           | 0                                                                          |
| Urinary tract infection                           | 0                                                                           | 1 (100.0%)                                                                  | 0                                                                          |

AE = adverse event; CSR = clinical study report; Gest. = gestational; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SAE = serious adverse event

AEs were coded using MedDRA Version 26.0.

Treatment-emergent adverse events are (1) any AEs that begin on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days, or (2) any AEs leading to premature discontinuation of study drug.

Multiple AEs were counted only once per participant per PT.

Preferred terms were presented by descending order of the total frequencies.

Source: GS-US-540-5823 Final CSR, Table 15.11.4.2

The CHMP noted that two out of three participants in cohort 5 had a baseline ordinal scale score of 2 (both with oxygen support of invasive mechanical ventilation) and all were treated in an intensive care unit. From this cohort, one participant experienced 5 SAEs (cardiopulmonary failure [2 events], acidosis, pneumothorax, and seizure). Acidosis is a known adverse event that can occur during intensive care. The other recorded SAEs of cardiopulmonary failure, pneumothorax and seizure could be related to the underlying  COVID-19  disease.  Of  note,  both  participants  with  invasive  mechanical  ventilation  had pulmonary infiltrates at screening. The recorded SAEs were not considered by the investigators to be related to the study drug. The participant in cohort 6 experienced a urinary tract infection that was not considered to be related to the study drug. The number and type of adverse events observed in the study are not higher or significantly different from those reported in previous RDV studies in adult and adolescent patients with underlying COVID-19 disease and are consistent with the known safety profile of RDV. Overall, there were no adverse events recorded during study participation that were considered to be related to the study drug. No new safety signals were identified.

## Laboratory findings

All  participants  had  a  graded  laboratory  abnormality.  Grade  3  and  4  laboratory  abnormalities  only occurred in Cohort 5 (Table 17). One participant had Grade 4 increased aPTT at Day 8 which was still Grade 4 at the time of the last coagulation assessment (Day 10) and had a Grade 1 increased direct bilirubin concentration (0.5 mg/dL) at Day 10 that met criteria for Grade 3 (0.5 mg/dL) at Day 30 due to the participant reaching &gt; 28 days of age.

One participant had Grade 3 increased creatinine at Day 2 that decreased to Grade 2 at Day 5. One participant had graded laboratory abnormalities reported due to sample collection error (haemolysis occurred) that were Grade 4 (increased aPTT, increased prothrombin time, and increased prothrombin/INR on Day 10) and Grade 3 (hyperkalaemia on Day 5). This participant also had Grade 2 hyperkalaemia at baseline/Day 1.

<div style=\"page-break-after: always\"></div>

Table 17. GS-US-540-5823: Grade 3 or 4 Laboratory Abnormalities (Safety Analysis Set)

|                                           | Cohort 5: 14 to < 28 Days, Gest. Age >37 Weeks, and Weight ≥ 2.5 kg (N=3)   | Cohort 6: < 14 Days, Gest. Age >37 Weeks, and Birth Weight ≥ 2.5 kg (N =1)   | Cohort 7: <56 Days, Gest. Age ≤37 Weeks, and Birth Weight ≥ 1.5 kg (N=1)   |
|-------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Maximum treatment-emergent toxicity grade | 3                                                                           | 1                                                                            | 1                                                                          |
| Grade 3                                   | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |
| Grade 4                                   | 2 (66.7%)                                                                   | 0                                                                            | 0                                                                          |
| Grade 3 or 4                              | 3 (100.0%)                                                                  | 0                                                                            | 0                                                                          |
| Chemistry                                 |                                                                             |                                                                              |                                                                            |
| Creatinine (increased)                    | 3                                                                           | 1                                                                            | 1                                                                          |
| Grade 3                                   | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |
| Direct bilinubin (increased)              | 2                                                                           | 1                                                                            | 1                                                                          |
| Grade 3                                   | 1 (50.0%)                                                                   | 0                                                                            | 0                                                                          |
| Serum potassium (hyperkalemia)            | 3                                                                           | 1                                                                            | 1                                                                          |
| Grade 3                                   | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |
| Coagulation                               |                                                                             |                                                                              |                                                                            |
| Prothrombin time (increased)              | 2                                                                           | 0                                                                            | 1                                                                          |
| Grade 4                                   | 1 (50.0%)                                                                   | 0                                                                            | 0                                                                          |
| aPTT (increased)                          | 3                                                                           | 1                                                                            | 1                                                                          |
| Grade 4                                   | 2 (66.7%)                                                                   | 0                                                                            | 0                                                                          |
| Prothrombin/INR (increased)               | 3                                                                           | 1                                                                            | 1                                                                          |
| Grade 4                                   | 1 (33.3%)                                                                   | 0                                                                            | 0                                                                          |

aPTT = activated partial thromboplastin time; DAIDS = Division of AIDS; Gest. = gestational; INR = international normalized ratio

The denominator for percentage is the number of participants in the Safety Analysis Set with at least 1 postbaseline value for the test umder evaluation, specified in each laboratory test row.

Participants were counted once for the maximum postbaseline severity for each laboratory test under evaluation. Severity grades are defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events,

Version 2.1, July 2017.

Source: GS-US-540-5823 Final CSR, Table 15.11.6.4.2

Overall, the CHMP considered that laboratory findings were consistent with the known safety profile in adult and adolescent patients with underlying COVID-19 disease. No new safety signals were identified.

## Discontinuation due to adverse events

No participant discontinued study participation due to adverse events.

## 2.5.1. Discussion on clinical safety

Overall, across Cohorts 5 to 7, no new safety concerns were identified in neonates less than 28 days of age weighing at least 1.5 kg and preterm neonates and infants less than 56 days of age weighing at least 1.5 kg who were administered RDV for up to 10 days. No adverse events were considered related

<div style=\"page-break-after: always\"></div>

to the study drug. There were no treatment-emergent deaths reported, and there were no participants who discontinued study drug prematurely due to an AE. Blood pressure, heart rate, and respiratory rate were  generally  stable  during  the  study.  Most  participants  (4  of  5  participants)  received  at  least  1 concomitant medication other than RDV for the treatment of COVID-19, including immune modulator medication, anti-inflammatory medication, and experimental antiviral medication.

The exposure results for the patient in Cohort 7 have been addressed in the discussion of the PK data.

## 2.5.2. Conclusions on clinical safety

Overall, across Cohorts 5 to 7, no new safety concerns were identified in neonates less than 28 days of age weighing at least 1.5 kg and preterm neonates and infants less than 56 days of age weighing at least 1.5 kg who were administered RDV for up to 10 days. The laboratory findings are consistent with the known safety profile in adult and adolescent patients with underlying COVID-19 disease.

No new safety signals were identified, although it has to be considered that the sample size is limited.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH initially submitted an updated RMP version (version 8.1) with this application at its start in December 2023. The RMP was updated with the  final  data  from  the  Study  GS-US-540-5823  which evaluated the safety, tolerability, PK and efficacy of remdesivir in participants from birth to &lt;18 years of age with COVID-19 (results for cohorts 5-7 are parts of this submission).

The initially proposed updates to the RMP were in the context of the application originally proposing to extend the Veklury indications to paediatric population weighing at least 1.5 kg with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment) and paediatric population weighing at least 1.5 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The following parts of the RMP were updated: Part I,  Part  II  -  Epidemiology,  Clinical  study  exposure,  Populations  not  studied  in  clinical  studies,  Postauthorization exposure, Part III, Part VI and annexes.

Subsequent updated versions, were submitted during the course of the assessment, up to RMP version 8.4, which reflected the final recommendations.

Notably, RMP version 8.3 included data from the drug-drug interaction studies (US-540-9013, GS-US611-6409, GS-US-540-6587) and QT/QTc study (GS-US-540-9053). In addition, clinical exposure and pregnancy FUQs were also updated within this RMP version.

RMP  version  8.4  was  provided  to  adapt  the  RMP  to  the  final  CHMP  recommendation  whereby  the extension of indication was granted only to paediatric patients at least 4 weeks of age and weighing at least 3 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19). RMP Parts I and VI were adapted accordingly.

The (main) proposed RMP changes were the following (updates are summarised or shown as track changes, when relevant):

<div style=\"page-break-after: always\"></div>

## Safety concerns

## Epidemiology of the indications and target population

The incidence of COVID-19 infection in neonates is lower than adult and older paediatric populations. This is possibly related to maternal antibodies that offer protection during the first few months of life {Carsetti 2020}. In the US, incidence rates ranged from 63.1 to 91.1 per 100,000 births {Wallace 2023},{Devin 2022}. Rates were similarly low in the EU, ranging from 56 to 153 per 100,000 births {Gale 2021, Goulding 2023}. Vertical transmission from mother to baby also appears to be low: under 1% to 3% of babies born to women with confirmed infection at time of birth had a neonatal infection {Hamidi 2022},{Norman 2021},{Goulding 2023},{Devin 2022}.

## Specific complications among neonates with COVID-19

As with paediatric cases of COVID-19, the data from large population-based studies suggest that cases in neonates are generally mild and have an overall good prognosis {Gale 2021},{Devin 2022},{Goulding 2023}. In a US study using encounter data across all care settings, only 7.7% of neonates diagnosed with COVID-19 had severe disease {Devin 2022}. Yet, in samples of neonates either receiving in hospital ward or neonatal intensive care, the fraction with severe disease was much higher at 26 to 42% {Gale 2021},{Akin 2022}, and the proportion requiring either respiratory support or supplemental oxygen varied from 13% to 33% {Scarsi 2021}. Admission to intensive care units ranged from 4.4% to 11%. {Devin 2022},{Gale 2021},{Goulding 2023}. However, these requirements may have been necessitated by other conditions such as prematurity and may not have been caused by COVID-19 infection.

Neonates with severe COVID-19 are more likely to have been born premature and to require respiratory support, receive a higher number of medications, and have longer overall length of stay (LOS) {Devin 2022}. They also have a higher incidence of comorbidities including cardiac abnormalities which may impact disease progression {Devin 2022}.

Although the majority of COVID-19 infections are either asymptomatic or mild, there is still risk of cardiac involvement including myocarditis. In neonates testing positive for SARS-CoV-2 who received care within neonatal intensive care units (NICUs), myocarditis was the most common major complication affecting around 6% of cases {Akin 2022}.

Multi-system inflammation syndrome in children (MIS-C) appears to be a rare complication in neonates, as in with children. In a study using healthcare encounter data from over 120 US health systems, only one suspected MIS-C case out of 918 positive SARS-CoV-2 diagnoses was identified {Devin 2022}.

Neonatal death from COVID-19 is possible although very rare. In the US {Devin 2022}, {Wallace 2023},{Hamidi 2022} and EU {Goulding 2023},{Gale 2021} mortality rates (all causes) ranging from 0% to 2% were reported. Devin and colleagues noted that one infant with suspected MIS-C died out of a total of 918 positive cases, and in Gale's study of 66 neonates with confirmed COVID-19 infection, one infant died due to a cause unrelated to COVID-19.

Preterm delivery is a leading cause of neonatal morbidity {Platt 2014}. However, studies comparing outcomes between preterm infants born to mothers testing positive for SARS-CoV-2 versus those testing negative did not find any significant differences with regards to development of respiratory distress syndrome, use of mechanical ventilation, duration of hospitalization, or mortality between groups {Yasa 2023},{Ciplak 2023},{Adams 2022}. In some studies {Yasa 2023},{Adams 2022}, a limited number of preterm infants with SARS-CoV-2 positive mothers were identified which may have

<div style=\"page-break-after: always\"></div>

impacted statistical power.

The PRAC noted that the MAH amended information regarding epidemiology of COVID-19 in neonates and provided information regarding complications in this patient population, which was acknowledged

## Nonclinical part of the safety specification

Conclusions from the drug-drug interaction studies (GS-US-611-6409, GS-US-540-6587) were included, which was endorsed.

## Clinical trial exposure

Table 18: Number of Participants in Gilead-Sponsored Clinical Studies and Compassionate Use Exposure

| Duration of Exposure (Days)                             | Persons (n)                                             | Person Days   |
|---------------------------------------------------------|---------------------------------------------------------|---------------|
| Healthy Volunteer Participants                          |                                                         |               |
| GS-US-399-1812                                          | 78                                                      | 78            |
| GS-US-399-1954                                          | 16                                                      | 165           |
| GS-US-399-4231                                          | 8                                                       | 8             |
| GS-US-399-5505                                          | 29                                                      | 237           |
| Total                                                   | 131                                                     | 488           |
| Hospitalized COVID-19 Participants                      |                                                         |               |
| IN-US-540-5755                                          | 240                                                     | 2080          |
| GS-US-540-5773                                          | 4838                                                    | 35406         |
| GS-US-540-5574                                          | 887                                                     | 5261          |
| GS-US-540-5823                                          | 58                                                      | 351           |
| GS-US-540-5912                                          | 163                                                     | 747           |
| Total                                                   | 6186                                                    | 43,845        |
| COVID-19 Participants not requiring Supplemental Oxygen | COVID-19 Participants not requiring Supplemental Oxygen |               |
| GS-US-540-9012                                          | 279                                                     | 829           |
| Total                                                   | 279                                                     | 829           |
| Other Volunteer Participants without COVID-19 infection | Other Volunteer Participants without COVID-19 infection |               |
| GS-US-540-9014                                          | 32                                                      | 32            |
| GS-US-540-9015                                          | 75                                                      | 81            |
| GS-US-540-6587                                          | 14                                                      | 140           |
| GS-US-540-9013                                          | 9                                                       | 26            |
| GS-US-540-9053                                          | 60                                                      | 60            |
| GS-US-611-6409                                          | 39                                                      | 39            |
| Total                                                   | 229                                                     | 378           |
| Grand Total                                             | 6825                                                    | 45,540        |

<div style=\"page-break-after: always\"></div>

The PRAC noted that the MAH updated tables in RMP Part II, Module SIII. Numbers of participants of the CARAVAN study (GS-US-540\\_5823), DDI studies (GS-US-540-9013, GS-US-540-6409, GS-US540-6587) and QT/QTc study (GS-US-540-9053) were included. Other tables in this RMP section were also acceptably updated.

## Populations not studied in clinical trials

Table 19.Exposure of Special Populations Included or not in Clinical Development Programs and Compassionate Use Program

| Type of special population   | Exposure                                                                                                                                                                                                                             | Considered to be Missing Information                                                                                                                                                                            |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pediatric patients           | As of 04 August 2023, 77 pediatric patients were included in the compassionate use program, 21 were included in Study GS-US-540-5773 and GS-US-540-5774, 3 were included in Study GS-US-540-9012, 58 were included in GS-US-540-5823 | No Rationale: The safety profile in adolescents aged 12 to < 18 years is not anticipated to differ from that in adults. Pediatric patients of at least 4 weeks of age and >3 kg are included in the indication. |

## Identified and potential risks

The MAH stated that no new safety concerns have been identified or reclassified since the submission of    the last RMP.

The PRAC noted that no new safety concern had been identified after reviewing the safety data from 5 paediatric participants included in cohorts 5-7 of the CARAVAN study.

AEs were observed in 3 from 5 participants and SAEs in 2 of them. None of the AEs/SAEs which occurred during the study was considered related to remdesivir and no discontinuation of the study medication was issued in the study. The SAEs were Grade 2 urinary infection in the participant in cohort 6 and five Grade 4 AEs in one of the participants from cohort 5. The participant was a 15days old boy with baseline weight of 2.8 kg who had a history of respiratory failure and was on IMV at baseline. He experienced cardiopulmonary failure on day 1. The SAEs subsided until day 4, when the participant experienced seizures which have been controlled by application of phenobarbital since day 4. His hospital stay was complicated by pneumothorax, acidosis and recurrence of cardiopulmonary failure at day 7.  This led to initiation of ECMO in the patient. None of these SAEs were considered related to RDV, severe COVID-19 and invasive treatment of the patient provide alternative explanation for occurrence of these SAEs.

No new safety concern has been identified after reviewing the laboratory data from 5 paediatric participants.

No update to the RMP PART II Modules SVII and SVIII is considered necessary based on information provided within the dossier in support of this application.

<div style=\"page-break-after: always\"></div>

Table 20.Summary of Safety Concerns

| Important Identified Risks   | None                     |
|------------------------------|--------------------------|
| Important Potential Risks    | None                     |
| Missing Information          | Safety in pregnant women |

Considering the very limited number of neonates (n= 4) and preterm neonates/infants (n=1) included in the study and very limited data regarding pharmacokinetics of the excipient sulfobutylether β -cyclodextrin sodium, the MAH was asked to summarize and discuss safety data from this patient population in future PSURs. The MAH agreed with the proposal. The proposal to extend the Veklury´s indications to neonates (i.e. paediatric patients younger than 4 weeks of age and weighing less than 3 kg) was withdrawn by the MAH.

## Pharmacovigilance plan

## Monitoring of data on treatment failure due to emerging variants

As requested by Pharmacovigilance Risk Assessment Committee (PRAC), data on treatment failure due to emerging variants will be monitored regardless of COVID-19 Public Health Emergency of International Concern status, from all available data sources, including but not limited to:

- Nonclinical data (antiviral activity and viral resistance) on new emerging variant of concerns or variant of interest (as defined by the WHO or ECDC)
- Spontaneous reports (retrieved by using Standardized Medical Dictionary for Regulatory Activities Queries Lack of efficacy/effect)
- Literature reports
- Marketing authorisation holder´s and partners clinical trial data
- Studies conducted by public health authorities

Cumulative data from the review will be summarized in a dedicated section of the PSUR. A dedicated paragraph will be included to present data from immunocompromised patients with the treatment duration of three days as there is a concern of potential development of viral resistance. If the review of the data leads to an impact on the benefit risk profile of RDV, appropriate variation (including the data, a benefit-risk discussion and any warranted product information updates) will be submitted to the agency within one month.

## Other Forms of Routine Pharmacovigilance Activities

Gilead has in place a general Business Continuity Plan (BCP) and annexed to this is a pandemic specific BCP setting forth the principles by which Gilead responds to increasing demand and/or decreasing capacity of its Pharmacovigilance (PV) system through active prioritization with a focus on critical products and key PV activities. At the same time and in order to manage through the pandemic and resource restraint situations without compromising compliance overall capacity enhancement and resource expansion is a key element of the preparedness and business continuity planning activity.

<div style=\"page-break-after: always\"></div>

## I.1. Additional Pharmacovigilance Activities

Table 21.Ongoing and Planned Additional Pharmacovigilance Activities

| Title                                                                                                                                                                                                                      | Rationale and Objectives                                                                                                                                                                                                   | Design and Populations                                                                                                                                                                                                     | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |

Amendment of the pharmacovigilance plan was requested in PSUSA/00010840/202305, when the MAH was asked to continue monitoring of the data on treatment failure due to emerging variants of SARS-CoV-2 regardless of COVID-19 pandemic status. The RMP was updated adequately.

## Risk minimisation measures

## Summary Table of Pharmacovigilance and Risk Minimization Activities by Safety Concern

| Safety Concern               | Risk Minimization Measures                                        | Pharmacovigilance Activities                                                                                                                                                                                                  |
|------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risk(s) | Important identified risk(s)                                      | Important identified risk(s)                                                                                                                                                                                                  |
| None                         | None                                                              | None                                                                                                                                                                                                                          |
| Important potential risk(s)  | Important potential risk(s)                                       | Important potential risk(s)                                                                                                                                                                                                   |
| None                         | None                                                              | None                                                                                                                                                                                                                          |
| Missing information          | Missing information                                               | Missing information                                                                                                                                                                                                           |
| Safety in pregnant women     | Routine risk minimization measures: SmPC section 4.6 PL section 2 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Post-marketing pregnancy report form Post-marketing pregnancy outcome report form Additional pharmacovigilance activities: None |

## RMP Annexes

The pregnancy and pregnancy outcome FUQs were renamed and slightly reorganized.

The changes made to the Pregnancy report and Pregnancy outcome report forms were noted and acknowledged by the PRAC without additional comments, as the content of the questionnaires remains very similar.

<div style=\"page-break-after: always\"></div>

## Overall conclusion on the RMP

The PRAC considered that the risk management plan version 8.4 was acceptable.

During the course of this procedure, version 9.0 of the RMP was approved as part of another variation that  concerned  only  the  RMP  (EMEA/H/C/005622/II/0062),  as  part  of  which  a  Cat.  3  additional pharmacovigilance activity (study CO-US-540-6127 - Covid Pregnancy Registry) was removed.

Therefore, the final RMP version endorsed by the CHMP with this procedure was the Risk Management Plan version 10, consolidating the changes approved in v8.4 with v9.0.

## 2.7. Update of the Product information

As a result of this group of variations, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC were proposed to be amended, to include the proposed new therapeutic indication, update the posology for adult and paediatric patients, add efficacy information from the GS-US-540-5823 study and to update pharmacokinetic parameters. The MAH initial proposals for the extended indications were:

Vekluryisindicated forthe treatmentofcoronavirus disease2019 (CoViD-19) in adults and paediatric patients (weighing at least 1.5 kg):

- adultsand paediatricpatients (at least 4 weeks of age and weighing at least 3 kg)withpneumonia requiring supplemental oxygen (low-orhigh-flow oxygen or other non-invasive ventilation at start of treatment)
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe CoviD-19

The CHMP however only partly supported the initially proposed extensions. The MAH, in line with the CHMP position, withdrew the type II variation to extend the indication for use in paediatric patients weighing at least 1.5 kg with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment) and agreed to the CHMP-recommended wording of the indication.

The other proposed extension of indications 'To extend the indication for use in paediatric patients weighing at least 1.5 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19' was considered acceptable, but with the age cut-off and the weight threshold consistent with the ones previously approved for with pneumonia requiring supplemental oxygen (4 weeks of age and weighing at least 3 kg). The following extension of indication was recommended:

Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients ( at least 4 weeks of age and weighing at least 3 kg ):

- with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other noninvasive ventilation at start of treatment)
- who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

The MAH agreed with the CHMP recommendations, and provided product information amended accordingly.

<div style=\"page-break-after: always\"></div>

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 2.7.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Veklury (remdesivir) was included in the additional monitoring list at the time of this procedure.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The human disease caused by SARS-CoV-2 has been designated COVID-19 and was first detected in Wuhan, China in December 2019. In most cases, COVID-19 presents as a mild-to-moderately severe, self-limited acute respiratory illness with fever, cough, and shortness of breath. Although children with COVID-19 frequently have mild or moderate symptoms, COVID-19 can result in severe disease. Children &lt; 1 year old and children with underlying disease are at a higher risk of developing COVID19-related pneumonia. The cumulative incidence of COVID-19-associated hospitalizations in children aged &lt; 18 years from 01 March 2020 to 17 June 2023 was 202 per 100,000 at Coronavirus Disease 2019-Associated Hospitalization Surveillance Network sites in the US. In Europe, the proportion of weekly reports of cases of COVID-19 infection in children was stable for the period from 17 July 2023 to 23 July 2023. Overall hospital admission rates were also stable over the same period. These findings are consistent with the availability of vaccines for adults and children. In those with severe disease, symptoms and radiological findings are similar to those of adults. Furthermore, underlying conditions such as pulmonary disease, immunocompromised state, or coexisting respiratory infections might predispose children to severe respiratory disease. Risk factors identified in children with COVID-19 infection for hospitalization and/or ICU admission include complex chronic diseases, type 1 diabetes, obesity, and cardiac and circulatory congenital anomalies. Prematurity has been identified as a risk factor for severe disease in children under 2 years old.

## 3.1.2. Available therapies and unmet medical need

Authorised COVID-19 treatments for children younger than 12 years of age consist only of remdesivir (Veklury), which is currently approved for children from at least 4 weeks of age and weighing at least 3 kg, with pneumonia requiring supplemental oxygen.

For adolescents aged 12 years and older and weighing at least 40 kg following treatments are available (EMA; Authorised COVID-19 treatments):

<div style=\"page-break-after: always\"></div>

- (tixagevimab and cilgavimab); used to prevent COVID-19 in adults and adolescents and to treat COVID-19 in adults and adolescents who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
- (casirivimab  and  imdevimab);  for  treating  COVID-19  in  adults  and  adolescents  who  do  not require supplemental oxygen and who are at increased risk of their disease becoming severe
- (sotrovimab); for treating COVID-19 in adults and adolescents who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

In addition, paediatric patients with COVID-19 are treated with relevant supportive care, including e.g., oxygen, mechanical ventilation and other life support, as required.

## 3.1.3. Main clinical study

Study GS-US-540-5823 was a single-arm, open-label study where pharmacokinetics, efficacy and safety of remdesivir in paediatric patients from birth to &lt; 18 years of age with COVID-19 was assessed. The study was planned with 22 study centres in Italy, Spain, the United Kingdom, and the United States.

This assessment focuses on data from Cohorts 5 to 7 of Study GS-US-540-5823 to support the proposed extension of indication.

## 3.2. Favourable effects

Efficacy endpoints were secondary and descriptively analysed and therefore these should be interpreted with caution.

The analysis population included 5 patients, who were included in three different age cohorts:

- Cohort 5: ≥ 14 days to &lt; 28 days of age, gestational age &gt; 37 weeks, and weight at screening ≥ 2.5 kg; 3 participants
- Cohort 6: 0 days to &lt; 14 days of age, gestational age &gt; 37 weeks, and birth weight ≥ 2.5 kg; 1 participant
- Cohort 7: 0 days to &lt; 56 days of age, gestational age ≤ 37 weeks, and birth weight ≥ 1.5 kg; 1 participant

Based on the data provided, three of the five patients with a baseline ordinal scale score of two or three had  an  improvement  of  ≥  2  points  during  study  participation.  Time  to  recovery,  defined  as  an improvement from a baseline score of 2 to 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7, ranged from 9 days (1 participant in cohort 5) to 19 days (1 participant in cohort 7).

Confirmed  negative  SARS-CoV-2  PCR  results  on  Day  2  through  Day  10  were  reported  for  all  5 participants.

Two of the 5 participants (1 each in Cohorts 5 and 6) were on high-flow oxygen from baseline to Day 7 and Day 5, respectively. Both participants were off oxygen support and breathing room air on Day 8 and Day 10 prior to being discharged from hospital on Day 9 and Day 13, respectively. The remaining 3 participants (2 in Cohort 5 and 1 in Cohort 7) were on IMV at baseline. The participant in Cohort 7 was switched to high-flow oxygen from Day 6 to Day 9 and then low-flow oxygen on Day 10. The participant was discharged from hospital on Day 19. The other 2 participants in Cohort 5 were on IMV from baseline until the last available assessment and were still hospitalized at Day 30.

<div style=\"page-break-after: always\"></div>

The PEWS total scores at baseline in Cohort 5 were 2 (33.3%; 1/3 participants), and 7 (66.7%; 2/3 participants). The participant in Cohort 6 had a baseline score of 6, and the participant in Cohort 7 had a  baseline  score  of  6.  By  Day  10,  all  5  participants  had  reductions  in  PEWS  total  score  (indicating improvement): in Cohort 5 there was a 2-point decrease in 1 participant, and a 1-point decrease in 2 participants. The participant in Cohort 6 had a decrease of 6 points, and the participant in Cohort 7 had a decrease of 5 points. The same results were observed at the time of last assessment.

The provided review of data from the MAH on the similarity of disease characteristics between paediatric and adult patients indicates that although there are physiological differences (e.g. organ maturation, liver  and  kidney  function,  body  size),  no  significant  discrepancies  have  been  identified  in  the characteristics of adults and paediatric patients of different age groups with regard to disease progression and clinical outcome. The characteristics of the symptoms and their intensity can vary between paediatric and adult patients. Certain comorbidities are unique, or more common in children, which increases their risk for severe COVID-19 (e.g. prematurity, genetic diseases, congenital heart disease). Risk factors for severe disease in the later Omicron era in the adult population include e.g. older age, immunocompromised status, haematological malignancy, diabetes, kidney disorders, coronary artery disease, chronic heart failure or cardiomyopathy, obesity, and multimorbidity. For paediatric patients, risk factors include e.g. prematurity, cardiovascular disease and circulatory congenital abnormalities, diabetes, obesity and neurological disorders. As per US CDC '[…] like adults, children and teens with obesity, diabetes, asthma or chronic disease, sickle cell disease or who are immunocompromised can also be at increased risk for getting very sick from COVID-19'. As discussed by the MAH, COVID-19associated hospitalisation rates increased rapidly in accordance with increased Omicron circulation in infants and children aged 0-4 years, a group not yet eligible for vaccination, resulting in hospitalisation rates approximately five times higher than during the period of the Delta virus variant. Data provided by the MAH show that infants aged &lt;6 months are the second largest demographic group hospitalised after the elderly aged &gt;75 years, accounting for 44% of hospitalisations during the Omicron peak. Of those &lt; 6 months, approximately 15% were identified as positive for COVID-19. Certain comorbidities are  unique  or  more  common  to  children  that  place  them  at  higher  risk  for  severe  COVID-19  (e.g. prematurity, genetic diseases, congenital heart disease); however, many risk factors for severe COVID19 are shared between children and adults. The risk factors for progression to severe COVID-19 as defined in PINETREE (GS-US-540-9012) appear to be consistent with those identified in the literature for both paediatric and adult patients.

The impact of new virus variants on the efficacy of RDV treatment in both paediatric and adult patients was discussed by the MAH. The dominant SARS-CoV-2 variant of concern as of 2022 remains Omicron, which accounts for &gt;98.8% of variants sequenced globally (as tracked by GISAID). With regard to the efficacy  of  RDV  against  new  virus  variants,  the  MAH  described  that  the  majority  of  amino  acid substitutions observed in SARS-CoV-2 variants occur in the envelope glycoprotein (spike), while the SARS-CoV-2 RdRp and the target of RDV are highly conserved. However, few amino acid changes in RdRp have been observed in circulating SARS-CoV-2 variants. The data presented do not indicate a lack of efficacy of RDV against these tested variants.

## Pharmacokinetics

The developed PopPK model based on adult and paediatric data accounted for weight based changes and included maturation functions to account for changes in the paediatric population from birth to adult age. Overall, diagnostic plots are considered acceptable and precision of parameter estimates overall was in an acceptable range. Moreover, the results of the bootstrap were found to be consistent with the final PopPK estimates for the final models. Simulations using the final PopPK model were performed for neonate cohorts of interest generated from relevant growth charts (Adults and Cohorts 1 to 3 and 8 from the NHANES growth chart; Cohorts 4 to 6 from the WHO growth chart; and Cohort 7

<div style=\"page-break-after: always\"></div>

from the Fenton Preterm growth chart) following the dosing regimens per protocol. The results of these simulations showed similar exposures in the virtual Cohorts 5 to 7 with the 2.5 mg/kg loading dose and the 1.25 mg/kg once-daily maintenance dose administered as IV infusion over 0.5 hours with the adult COVID-19 patient exposures.

## 3.3. Uncertainties and limitations about favourable effects

Due to the single-arm design of GS-US-540-5823, the lack of a control arm and the fact that only descriptive efficacy data were presented, efficacy data are of limited value. In addition, the total number of five participants in cohorts 5, 6 and 7 is rather small and the interpretation of individual data points and the efficacy data in general should be considered with caution. Overall, no firm conclusion can be drawn regarding efficacy in the intended paediatric indication.

The adequacy of the doses for neonates (cohorts 5, 6 and 7) was questioned. With the doses initially proposed by the popPK model and investigated in the paediatric study (GS-US-540-5823), the observed data in the neonate cohorts showed that exposure was higher than in adults and older paediatric patients, especially  for  the  most  relevant  compound  GS-441524.  The  extrapolation  approach  was  aimed  at defining doses that lead to same exposures compared to adults and older paediatric patients. Since this aim was not achieved with the doses proposed by the popPK model, the model does not yet adequately describe the PK in the neonate cohort but needs to be refined to better align with the observed data. It is recognized that a dose reduction to half (2.5 mg/1.25 mg) has already been proposed for the term neonates 2-4 weeks old (C5) by the company. These new doses needed to be justified with the refined model. Subsequently, for cohorts 6 and 7 new doses also needed to be defined according to the refined model.

The need for refinement of the popPK model might especially concern the maturation of the elimination, but also other factors (e.g. total body water, body composition (adipose tissue portion), specific enzyme functions) might need to be considered. Subsequently, sensitivity analyses with respect to dose selection should be conducted and VPCs conducted for the refined model focussing on the age and weight ranges impacted by the current variation also including the specific age range preterm population. Additionally, the proposed dosing for subjects above 28 days is questioned. This dosing should be discussed and justified and supported by simulations in the relevant age cohorts, i.e. simulations for subjects 29-56 days  weighing  1.5-2.9  kg  and  simulations  for  subjects  29-56  days  weighing  3+  kg.  The  dose proportionality is demonstrated between 3 to 225 mg, therefore patients weighing 1.5 kg and treated with  1.25  mg/kg,  should  take  1.88  mg  (rounded  to  2  mg)  that  is  outside  the  range  of  dose proportionality.  This  implies  that  for  doses  below  3  mg,  the  behaviour  of  the  exposure  is  unknown hampering the possibility to make predictions on the exposure. This was discussed by the MAH and the result was as follows:

The available popPK models do not adequately describe the PK in the neonate cohorts. Therefore, no dosing recommendations can be given to support exposure matching. It is considered that more data in the  neonate  populations  would  be  needed  to  inform  the  model  and  subsequently  allow  for  dosing recommendations in this vulnerable population. However, no new data have been provided, so that high uncertainties  remain  in PK,  especially in clearance, for the neonatal  groups,  so  that  dosing recommendations could not be supported by the CHMP based on the existing models. Due to this lack of a  reliable  model  to  characterise  PK  from  birth  onwards,  robust  enough  to  allow  simulations  for  the youngest patient population, the CHMP only supported a part of the initially proposed extensions of indications.

In line with the CHMP position, the MAH withdrew the type II variation application to extend the indication for Veklury to use in paediatric patients weighing at least 1.5 kg with pneumonia requiring supplemental

<div style=\"page-break-after: always\"></div>

oxygen  and  agreed  to  the  CHMP-recommended  wording  of  the  indication,  thus  addressing  the uncertainty.

As discussed by the MAH, risk factors for progression to severe COVID-19 disease in the later Omicron era in the paediatric and adult populations are limited by the number of comparative analyses assessing risk in the context of the Omicron virus variant. The available data focus on American, Asian and Middle Eastern populations.

## 3.4. Unfavourable effects

In total, five paediatric participants received up to ten doses of RDV during the GS-US-540-5823 trial (cohorts 5, 6 and 7). In general, RDV was well tolerated and no adverse events were considered to be related to the study drug. No treatment-emergent deaths were reported and there were no participants who discontinued treatment prematurely due to an AE.

No new safety concerns were identified in neonates less than 28 days of age weighing at least 1.5 kg and in preterm neonates and infants less than 56 days of age weighing at least 1.5 kg.

## 3.5. Uncertainties and limitations about unfavourable effects

The  safety  data  from  only  five  participants  from  different  cohorts  were  considered  limited  to  draw conclusions on the safety profile of RDV in this patient population. Overall, the reported results are consistent with the known safety profile of RDV in adult and adolescent patients with underlying COVID19 disease.

In the cohorts 5 to 7 only hospitalised participants were assessed. As the PK data for RDV showed no clinically significant differences between hospitalised and non-hospitalised adult participants and the data from a virtual paediatric patient population, the clinical safety of this likely healthier paediatric population should not be of concern. This is further supported by the fact that the duration of treatment for this patient population is only three days, compared to 5 to 10 days for paediatric patients with pneumonia and requirement of supplemental oxygen.

The available popPK models do not adequately describe the PK in the neonate cohorts. The available very limited data (cohort 5 n=3, cohort 6 n=1 and cohort 7 n=1) give indications of higher exposure compared to adults and older paediatric age cohorts. Since no reliable model is available, no dosing recommendations can be given for the neonate cohorts. It was considered that more data in the neonate populations would be needed to inform the model and subsequently allow for dosing recommendations in this vulnerable population. As no new data were provided, high uncertainties remained in PK for the neonatal  groups,  especially  with  regards  to  clearance,  so  dosing  recommendations  could  not  be supported based on the existing models.

The MAH agreed to summarise and discuss neonatal and preterm safety data in future PSURs.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

T ab le 22. Effects Table for Veklury for the treatment of coronavirus disease 2019 in paediatric patients (data cut-off: 01 June 2023) based on CARAVAN Study (GS-US-540-5823)

| Effect                        | Short description                               | Treatment                                                            | Treatment                                                                                                                                                                                                                                                                                                                                                   | Uncertainties / Strength of evidence                                                                                                                                                                                                                                                 |
|-------------------------------|-------------------------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| General                       | General                                         | General                                                              | General                                                                                                                                                                                                                                                                                                                                                     | Unc: Lack of a control arm Unc : Limited number of participants                                                                                                                                                                                                                      |
| Favourable Effects            | Favourable Effects                              | Favourable Effects                                                   | Favourable Effects                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                      |
| Paediatric patient population | Observed concentrations and model-predicted AUC | Paediatric patients aged at least 4 weeks and weighing at least 3 kg | Exposure for GS- 441524 within the 5 th and 95 th percentiles of exposures in hospitalised adult participants with severe COVID-19 pneumonia on supplemental oxygen and in non-hospitalised adult participants with COVID-19 at risk of disease progression and not on supplemental oxygen, 50 th percentile AUC comparable or slightly lower than in adult |                                                                                                                                                                                                                                                                                      |
| patients Unfavourable Effects | patients Unfavourable Effects                   | patients Unfavourable Effects                                        | patients Unfavourable Effects                                                                                                                                                                                                                                                                                                                               | patients Unfavourable Effects                                                                                                                                                                                                                                                        |
| Paediatric patient population | Observed concentrations and model-predicted AUC | Paediatric patients below 4 weeks of age or below 3 kg bodyweight    | Exposure for GS- 441524 higher compared to older paediatric and adult patients, 25 th percentile AUC of neonates above 75 th percentile of AUC in adult patients                                                                                                                                                                                            | Unc: observed concentrations indicate higher exposure compared to older patients, thus prone to safety risks Unc: no adequate model available to describe PK in neonates Unc: No model available fit for purpose to conduct simulations supporting dose recommendations for neonates |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The extrapolation of adult efficacy and safety data to paediatric patients is based on matching paediatric and adult systemic exposures.

<div style=\"page-break-after: always\"></div>

From  study  GS-US-540-5823,  no  firm  conclusion  can  be  drawn  regarding  efficacy  in  the  intended paediatric indication.

RDV was well tolerated and no new safety concerns were identified in neonates less than 28 days of age weighing at least 1.5 kg and in preterm neonates and infants less than 56 days of age weighing at least 1.5 kg.

## 3.7.2. Balance of benefits and risks

PK, efficacy and safety data from the final analysis of the Phase 2/3 GS-US-540-5823 study, cohorts 5 to 7, have been included in this submission to extend the indication to include treatment of COVID-19 in paediatric patients.

No new safety signals were identified and the safety data reported are consistent with the known safety profile of RDV treatment in adult and adolescent patients with underlying COVID-19 disease.

The adequacy of the doses for neonates (cohorts 5, 6 and 7) was questioned. With the doses initially proposed by the popPK model and investigated in the paediatric study (GS-US-540-5823), the observed data in the neonate cohorts showed that exposure was higher than in adults and older paediatric patients, especially  for  the  most  relevant  compound  GS-441524.  The  extrapolation  approach  was  aimed  at defining doses that lead to same exposures compared to adults and older paediatric patients. Since this aim was not achieved with the doses proposed by the popPK model, the model did not adequately describe the PK in the neonate cohort but needed to be refined to better align with the observed data.

The updated model provided in the responses did not improve the model fit to the observed data and therefore is  not  suitable  to  characterise  the  PK  in  the  neonate  cohorts  and  support  dosing recommendations. The available very limited data (cohort 5 n=3, cohort 6 n=1 and cohort 7 n=1) give indications of higher exposure (especially for metabolite GS-441524, since this is most closely related to the active form of RDV) compared to adults and older paediatric age cohorts. Since no reliable model is available, no dosing recommendations can be given for the neonate cohorts. It is considered that more data in the neonate populations will be needed to inform the model and subsequently allow for dosing recommendations in this vulnerable population. However, no new data have been provided, so that high uncertainties  remained  in  PK,  especially  in  clearance,  for  the  neonatal  groups,  so  that  dosing recommendations cannot be supported with the existing models.

Due to the lack  of  a  reliable  model  to  characterise  PK  from  birth  onwards,  robust  enough  to  allow simulations for the youngest patient population, the CHMP only supported a part of the initially proposed extensions of indications. The MAH, in line with the CHMP position, withdrew the type II variation for Veklury to extend the indication for use in paediatric patients weighing at least 1.5 kg with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment) and agreed to the CHMP-recommended wording of the indication.

The other proposed extension of indications 'To extend the indication for use in paediatric patients weighing at least 1.5 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19' was considered acceptable with the age cut-off and weight threshold consistent with the ones previously approved for with pneumonia requiring supplemental oxygen (i.e.: 4 weeks of age and weighing at least 3 kg). The MAH agreed with the CHMP recommendations, and provided product information amended accordingly.

The provided review of data from the MAH on the similarity of disease characteristics of paediatric and adult patients indicates that although there are physiological differences (e.g. organ maturation, liver and kidney function, body size), no significant discrepancies have been identified in the characteristics of adults and paediatric patients of different age groups with regard to disease progression and clinical

<div style=\"page-break-after: always\"></div>

outcome. The characteristics of the symptoms and their intensity can vary between paediatric and adult patients. Certain comorbidities are unique, or more common, in children, which increases their risk for severe COVID-19 (e.g. prematurity, genetic diseases, congenital heart disease). In general, the severity of the disease tends to be less severe in children; however, the general characteristics of the disease and many risk factors for severe COVID-19 are similar in children and adults.

The impact of new virus variants on the efficacy of RDV treatment in both paediatric and adult patients were discussed. The data presented do not indicate a lack of efficacy of RDV against these tested variants.

## 3.8. Conclusions

The overall benefit-risk of Veklury for the extension of indications 'To extend the indication for use in paediatric patients at least 4 weeks of age and weighing at least 3 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19' is positive.

The following wording for the indications section is recommended for approval:

Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and paediatric patients ( at least 4 weeks of age and weighing at least 3 kg ):

- adults  and  paediatric  patients  (at  least  4 weeks  of  age  and  weighing  at  least  3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of paediatric patients who are at least 4 weeks of age and weighing at least 3 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 for Veklury, based on final results from study GS-US-540-5823; this is a Phase 2/3 single-arm, open-label study to evaluate the  safety, tolerability, pharmacokinetics, and efficacy of remdesivir in participants from birth to &lt; 18 years of age with COVID-19. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP is approved with this variation.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB, and to the Risk Management Plan, are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0439/2023 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.